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CHAPTER 1 
INTRODUCTION AND AIM OF THE STUDY 
INTRODUCTION AND AIM OF THE STUDY 
The elderly are the most fastly growing age group in The Netherlands 
and in many other western countries. With increasing age, multiple 
disease states (multiple pathology) are more common; it is therefore 
not surprising that the elderly are consumers of many drugs 
(polypharmacy). In old people, as compared with the young, the 
pharmacokinetics and pharmacodynamics of several drugs are alter-
edl-4; it is often necessary to adjust the dose of drugs and a 
thorough knowledge of what might be called geriatric pharmacology^ 
is essential for appropriate drug treatment. 
Due to the altered response to drugs and due to polypharmacy (giving 
rise to interactions that are often unpredictable), adverse drug 
reactions (ADR) are more frequent in the aged. Studies have shown 
that in patients over age 70 a twofold increase of ADR is seen as 
compared with the youngG. To prevent iatrogenic disease it is 
therefore of importance to treat elderly patients, in general, with 
small doses of drugs; the dosage may be increased on the basis of 
clinical effects and in the absence of side effects. 
Assessment of a phenomenon such as ADR is sometimes easy, but more 
often it is difficult to give full proof that a disease is drug-
induced. The spontaneous (i.e. voluntary and unasked) reports of 
doctors in general practice are the main method in the detection of 
ADR in the society8»9t in Europe the reporting system with the 
yellow card to the centres for monitoring adverse drug reactions has 
proved to be of valued, in these centres ADR are assessed and 
exchange of information with other centres takes place. The detection 
of an ADR becomes more difficult when a drug induces a disease, 
whereas the drug was prescribed precisely to prevent that disease. 
The disease may be ascribed to a failure of therapy and the possibi-
lity of an ADR may not be considered by the clinician. 
This thesis comprises studies on stroke as a possible side effect of 
antihypertensive treatment in the elderly. The study was prompted by 
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an observation of Gribnau (personal communication). A close elderly 
relative of his suffered a stroke shortly after her general practi-
tioner prescribed furosemide because of hypertension. She recovered 
completely; the furosemide was stopped. After a few monthsthe general 
practitioner again prescribed furosemide because of hypertension. 
Shortly thereafter stroke recurred and proved to be irreversible. 
Neurologists, asked about their familiarity with this "side effect of 
antihypertensive treatment", considered it not uncommon. However, in 
the literature only a few cases have been reported and stroke as side 
effect of antihyoertensive treatment with furosemide has not been 
reported at all to the Netherlands Centre for Monitoring Adverse Drug 
Reactions. 
The aim of the study was to answer the following questions: 
- does stroke occur as a side effect of antihypertensive treatment? 
- which drugs are responsible for this ADR? 
- are the elderly especially at risk to develop this ADR? 
- what is the frequency of this ADR in patients hospitalised for 
recent stroke? 
Since hypertension is the most powerful risk factor for stroke^ 
and antihypertensive treatment is intended to prevent it, the detec-
tion of stroke as side effect of antihypertensive treatment is 
difficult. For assessment of ADR, to define side effects as unlikely 
(or doubtful), possible, probable or definite, several methods and 
algorithms are in usel4"16. The value of these methods and algo-
rithms in the assessment of stroke as ADR of antihypertensive treat-
ment is discussed in Chapter 2. 
A review of cases of drug-induced cerebral ischaemia reported in the 
literature is given in Chapter 3. 
Since the outcome of stroke is often an irreversible hemiparesis and 
patients are rehabilitated in nursing homes, if possible, we expected 
to find cases in this population. We asked all medical directors of 
Dutch nursing homes (n=322) to report suspected cases of drug-induced 
stroke; this inquiry is presented in Chapter 4. 
To obtain information on the frequency of the suspected ADR, 100 
patients admitted with cerebral infarction or transient ischaemic 
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attack (TIA), were studied in the 3 weeks before the event, as to 
blood pressure course and as to signs of hypovolaemia; this study is 
presented in Chapter 5. 
Of the 100 patients studied, one category was considered separately; 
this group comprised only patients receiving antihypertensive medica-
tion. This study, including case histories, is presented in Chapter 
6. 
In the first days after stroke, blood pressure is usually increas-
edl7~20. n iS still under discussion whether post-stroke hyper-
tension should be treated21-23# There are reports that blood pres-
sure reduction after stroke might be dangerous and aggravate cerebral 
ischaemia24< we studied the natural course of blood pressure be-
fore, the first days after and several months after stroke; these 
data are presented and discussed in Chapter 7. 
The mechanism of the blood pressure increase after stroke is still 
unknown. A relationship with the stress of the event has been sug-
gested, but also neuronal (dys)regulation25,26# ye studied prelimi-
narily the relation between the course of blood pressure and both 
plasma and urinary catecholamines on the first three days after cere-
bral infarction; this study is presented in Chapter 8. 
The final chapter gives a summary of the findings and formulates con-
clusions. 
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CHAPTER 2 
STROKE AFTER STARTING ANTIHYPERTENSIVE TREATMENT; 
ASSESSMENT OF A POSSIBLE CAUSAL RELATIONSHIP 
PAF Jansen, RHB Meyboom, FWJ Gribnau, BPM Schulte 

INTRODUCTION 
Adverse drug reactions (ADR) are drug-induced clinical manifesta-
tions, that are noxious, unintended and occur at doses normally used 
in mani, jhey
 are a considerable cause of morbidity and sometimes 
even lead to death. Drugs may induce a large variety of symptoms and 
disorders, and in many patients drugs should be considered as a pos-
sible cause of disease. Efficient methods of detecting ADR include 
the yellow card reporting system in Europe2, and the spontaneous 
reporting system in the USA^; published anecdotal reports are also 
considered of great v a l u e d . 
Assessment of the relationship between a drug and a suspected adverse 
reaction is, however, notoriously difficult. Only very rarely is a 
disorder pathognomonic for a drug, and diagnostic tests to confirm 
involvement of the drug are mostly not available. As a rule, anv me-
dical diagnosis entails a certain amount of incertitude. In many dis-
eases in which there is no critical test, a systematic procedure of 
diagnosis has been developed, which includes sets of essential and 
secondary criteria. Accordingly, a number of diagnostic models have 
been designed for assessment of the likelihood of a disorder being 
drug-induced^"!^. The purpose of these efforts was to unify the 
procedure and to improve the objectivity of diagnosis. These ap-
proaches usually take into account a number of critical questions, 
have the form of an "algorithm" and provide a calculated degree of 
likelihood which is expressed in an addition sum and an associated 
causality term, e.g. unlikely, possible, probable and definite. 
We have elsewhere provided evidence that starting of antihypertensive 
treatment in the elderly may provoke cerebral ischaemia and even 
stroke when the fall of blood pressure is too rapid or too steep^. 
In those patients reasons to assume a causal relation with the treat-
ment were: 
- the apparent association in time; 
- a marked fall of blood pressure after the event, as compared with 
that prior to treatment, while usually there is an increase of 
blood pressure after stroke; 
- signs of circulatory volume depletion. 
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In an attempt to improve the causal diagnosis in our patients, we 
applied the best-known druq-reaction assessment algorithms as des-
cribed in literature7»^. 
Assessment of cerebral infarction as ADR to antihypertensive treat-
ment 
The algorithm of Kramer et al.7 comprises six major axes of deci-
sion strategy with a scoring system incorporated in each axis. An 
outline of the scoring strategy is presented in Table I. The first 
axis concerns previous general experience with the drug. In our cases 
furosemide was prescribed (in a non-slow-release dosage form), 
because of hypertension; the indication for prescribing furosemide is 
usually congestive heart failure; it is not clear how often furose-
mide is prescribed for hypertension. One study mentions use of 
furosemide because of hypertension in 1.4% of the patients^. 
Recause the drug is widely used, enough clinical experience is 
available to make it likely that most ADR due to furosemide have been 
reported. The question remains whether this completeness of case 
finding may also be assumed regarding furosemide in the treatment of 
hypertension. To our knowledge the literature comprises 4 reports on 
signs of cerebral ischaemia after use of furosemide, given in 
combination with other antihypertensive drugs^ 7 -^. Because the 
clinical manifestation is not well known, but previously reported, 
the score on axis I is 0. 
Axis II concerns alternative causes of the clinical manifestation, 
e.g. underlying clinical conditions, or diagnostic or therapeutic 
interventions. Because hypertension is the most important risk factor 
for stroke20t the clinical manifestation (i.e. cerebral infarction) 
can be explained as a result of the blood pressure increase, and is a 
good alternative candidate. The score is -1. 
Axis III concerns relationship in time between start of the drug and 
clinical manifestation. Because furosemide was started within 2 weeks 
before the event and in that time may have caused hypovolaemia, a 
time relationship may be present and the score on axis III can be +1. 
Axis IV concerns evidence of overdose of the drug. It could be assum-
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TABLE I 
Scoring strategy according to Kramer et al.7. Definite >6, probable 4-5, 
possible 0-3, unlikely <0 (CM = clinical manifestation) 
+1* 
Axis I CM well accepted as AdR 
to suspected druq 
Axis I I a) No good al ternat ive 
candidate(score +2); 
or 
CM is not well known CM previously 
or druq is new unreported as ADR 
to well-known drug 
Candidate(s) ex is t . Good al ternat ive 
but no qood ones candidate 
Otherwise unexplained 
exacerbation or 
recurrence of underlyinq 
i l lness (score +1) 
Axis I I I Timing as expected for ADR 
for th is druq-CM oair 
Timinq equivocal 
or nonassessable 
Timinq inconsistent 
for ADR for th is +1 
druq-CM pair 
(score -2) 
Axis IV Drug level or other data 
provide uneauivocal 
evidence of overdose 
Unobtained, unknown 
or equivocal level 
or other evidence 
of overdose 
Drug level strongly 
against overdose 
Axis V a) CM improves sui tably 
after dechallenqe; or 
a) CM improved, but a) CM imprnves wi th-
deqree or rate out dechallenqe; 
are unexpected;or or 
b) Nature of CM prevents b) CM is treated by b) Potent ia l ly re -
assessment of dechallenqe aux i l iary versible CM f a i l s 
for otherwise l i k e l y maneuver to imnrove after 
ADR*** dechallenqe 
Axis VI CM unequivocally recurs 
or exacerbates 
on rechallenqe 
a) No rechallenge 
attemnted; or 
b) Response of CM 
obscured by 
aux i l ia ry maneuver 
CM f a i l s to recur or 
exacerbate on 0 
rechallenge 
Total score 0 
* Except where noted as +2 
** Except where noted as -2 
*** ADR is likely when score on axis is I-IV > 3 
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ed that the patients took the prescribed dose and that there is no 
evidence of overdose. The score is 0. 
Axis V concerns dechallenge; in our cases dechallenge cannot be 
assessed because withdrawal of the causative agent is independent of 
the resolution of organ damage. In the case of cerebral infarction 
the outcome of the damage is often irreversible. The nature of the 
clinical manifestation therefore prohibits assessment of dechallenge. 
As the AOR is "not likely", and the score on axis I-IV is <3, the 
score on axis V is 0. 
Axis VI concerns rechallenge; when stroke proved to be irreversible, 
rechallenge is of no value; when the patients after stroke improve, 
rechallenge should not be attempted in our opinion, because of the 
seriousness of the inspected ADR and chance for irreversibility of 
the clinical manifestation. The score on the last axis is 0. The to-
tal score according to the algorithm is 0 and the ADR is assessed as 
possible. 
As Naranjo et al.8 found the algorithm of Kramer et al.7 too 
detailed and time-consuming, they developed a simple method to assess 
the causality of ADR (Table II). In this method the answer to the 
first question, concerning conclusive reports on cerebral infarction 
as side e f ct of antihypertensive treatment with furosemide, is 
negative (score 0). The second question, concerning time relation-
ship, is positive and gives a score of +2. The third question, 
concerning improvement after discontinuation of the drug is to be 
answered with no (score 0) because of the frequent irreversibility of 
the clinical manifestation. For the same reason it is difficult to 
answer question 4 (readministration of the drug), question 6 (reap-
pearance of the reaction after administration of a placebo), question 
8 (relation with dose) and question 9 (previous exposure to similar 
drugs) in all cases giving score 0. The fifth question on alternative 
causes, has to be answered yes, because hypertension is a good alter-
native candidate (score -1). The answer to question 7, concerning 
blood levels of the drug, is no (score 0). Finally, the answer to 
question 10 (objective evidence of the adverse event) may be answered 
positively when the signs of stroke are considered as objective 
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TABLE I I 
Scoring strategy according to Naranjo et a l . 8 . Definite >9, probable 5-8, 
possible 1-4, doubtful <0. 
Yes No Do not know Score 
1 . Are there previous conclusive reports on +1 0 0 0 
this reaction? 
2. Did the adverse event appear after the +2 -1 0 +2 
suspected drug was administered? 
3. Did the adverse reaction improve when the + 1 0 0 0 
drug was discontinued or a specific 
antagonist was administered? 
4. Did the adverse reaction reappear when the + 2 - 1 0 0 
drug was readministered? 
5. Are there alternative causes (other than -1 +2 0 -1 
the drug) that could on their own have 
caused the reaction? 
6. Did the reaction reappear when a placebo - 1 + 1 0 0 
was given? 
7. Was the druq detected in the blood (or other + 1 0 0 0 
fluids) in concentrations known to be toxic? 
8. Was the reaction more severe when the dose + 1 0 0 0 
was increased, or less severe when the dose 
was decreased? 
9. Did the patient have a similar reaction to +1 0 0 0 
the same or similar drugs In any previous 
exoosure? 
10. Was the adverse event confirmed by any + 1 0 0 +1 
objective evidence? 
Total score +2 
DISCUSSION 
According to two commonly used grading methods for assessing ADR, 
cerebral infarction as side effect of antihypertensive treatment with 
furosemide was regarded as possible. Another important algorithm 
(that of Karch and Lasagna)^, is not discussed because of its com-
plexity; according to this algorithm the ADR was assessed as 
unrelated, because the event could be expected in hypertensive 
patients. Nevertheless, we believe that there are factors, not 
incorporated in the above mentioned algorithms and methods, that 
point to furosemide treatment as the cause of the cerebral infarction 
in the three patients mentioned. Firstly, attention must be given to 
the fall in blood pressure; a fall in blood pressure after starting 
antihypertensive treatment is intended and to be expected. However, a 
marked fall in blood pressure after stroke is uncommon; after stroke 
blood pressure is usually increased and studies have pointed out 
that, in 95% of the patients with stroke, blood pressure was 
increased as compared with pre-stroke values21-24t Most patients 
with cerebral infarction we studied, also had an increased blood 
pressure after stroke. The fall in blood pressure in the three 
patients* we suspected of having the alleged ADR, was greater than in 
any other patient we studied, and is therefore remarkable. Normally, 
the brain is protected against blood pressure fluctuations by auto-
requlation: when blood pressure rises, cerebral vessels constrict and 
when blood pressure falls, cerebral vessels dilate, resulting in a 
constant cerebral blood flow in ranges of 60 to 150 mmHg mean 
arterial blood pressure (MAP)25, Beyond these values, there is 
failure of autoregul at i on. In patients with hypertension, however, 
the autoregulatory curve is shifted to the right, resulting in 
impairment of blood flow already at levels higher than 60 mmHg25. 
Another point of interest is the age of the patients. All three 
patients were elderly (67, 72 and 72 years). It is known that in the 
elderly a fall in blood pressure cannot be compensated as adequately 
* The case histories of these patients are presented in Chapter 6. 
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as in the young. The baroreflex is less sensitive^6 and there may 
be failure of autoregul at i on of the brain in old ageZ?, making 
cerebral blood flow directly dependent on blood pressure. A relative-
ly minor fall in blood pressure can cause cerebral ischaemia in such 
a situation. A last point of importance are the laboratory data of 
the three patients, providing evidence of hypovolaemia induced by the 
furosemide diuresis (high haematocrit values >0.48 1/1 and relatively 
high plasma albumin concentrations >42 q/1). Cerebral blood flow 
decreases also with high haematocrit (>0.46 1/1), resulting in 
cerebral ischaemia^S. Although clinical evidence suggests that 
cerebral infarction was induced by antihypertensive treatment with 
furosemide in the 3 elderly hyoertensive patients, the commonly used 
algorithms and methods give little^iö or no6 support. 
There are many difficulties in detecting stroke as ADR to antihyper-
tensive treatment. Since hypertension is the major risk factor for 
stroke, the development of stroke a few days after starting anti-
hypertensive treatment may be a coincidence. Because of a persistent 
neurological deficit after stroke, dechallenge and rechallenge are of 
no value in most cases. In the case of reversibility of the signs, 
rechallenge is not feasible for ethical reasons. The literature 
reports one case of retinal ischaemia as side effect of oral nifedi-
ріпе^Э; after cessation of the drug the signs disappeared; after 
rechallenge with nifedipine, blindness as a consequence of retinal 
ischaemia returned; after cessation of nifedipine the blindness 
proved to be reversible again. 
In conclusion, the algorithms used to assess stroke as ADR to anti­
hypertensive treatment are of little value. Invariably there was a 
low score, mainly because the ADR was considered not to be well 
known, hypertension as a cause of stroke is a good alternative and 
dechallenge and rechallenqe are of no value in view of the oossible 
irreversibility of stroke. In the case of a suspected adverse 
reaction that is not well-known and resembles an otherwise not 
uncommon disorder, a careful search is needed for signs or symptoms 
that are unusual in the spontaneous disease. Uniformity of diagnosis 
may only be achieved in a sensible way with the aid of a specially 
designed algorithm. 
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CHAPTER 3 
CEREBRAL ISCHAEMIA AND STROKE AS SIDE EFFECT OF ANTIHYPERTENSIVE 
TREATMENT; SPECIAL DANGER IN THE ELDERLY 
A review of cases reported in literature 
PAF Jansen, BPM Schulte, FWJ Gribnau 
Submitted for publication 
SUMMARY 
There are few reports on cerebral ischaemia or stroke as possible 
side effect of antihypertensive treatment. This review presents cases 
reported in the literature. Especially elderly hypertensive patients 
seem to be at risk for this unintended and paradoxical side effect of 
antihypertensive treatment, because they are more sensitive than the 
young for complications, when a rapid and/or marked fall in blood 
pressure is obtained. Possible explanations for the increased 
predisposition to complications are discussed. For antihypertensive 
treatment in the elderly it is advisable to start with a small dose 
of an appropriate antihypertensive drug, aiming at a slow decrease in 
blood pressure. 
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INTRODUCTION 
Hypertension is the most important risk factor for strokel>2. In 
the aged, systolic hypertension in particular is a powerful contri-
butor to stroke incidence3-5. Effective antihypertensive treatment 
has proved to reduce morbidity and mortality from stroke, also in the 
elderly6-9. in the reduction of stroke recurrence, antihypertensive 
treatment is of benefit as welllO»ll; in the aged however, 
effective antihypertensive treatment has not been proved to prevent 
stroke recurrence^,13. in an elderly patient with hypertension one 
should at least consider starting antihypertensive treatment, 
although there is no consensus about the level of diastolic or 
systolic pressure above which one should start treatment. In common 
clinical practice the rule is to institute antihypertensive drugs in 
elderly patients with hypertension (i.e. systolic >160 imHg and/or 
diastolic >95 mmHg according to the WHO^) with a sustained 
diastolic pressure of 115 mnHg or more, with diastolic pressures in 
the range 100-114 mmHg in the presence of complications or a systolic 
pressure greater than 180 mmHgl5,16# 
Apart from beneficial effects, drugs also cause negative effects.Some 
are dose-independent, but most are dose-dependent. Especially in the 
elderly, one should beware of side effects of drugs in view of 
changes in pharmacokinetics, pharmacodynamics and of polypharmacy 
often needed for multiple pathologyl7»18. 
We studied stroke as a side effect of antihypertensive treatment in 
the elderlyl9. This review of the literature presents the other 
reported cases on cerebral ischaemia or stroke as possible side 
effect of antihypertensive treatment and on other drugs inducing 
hypotension. 
Cerebral ischaemia due to drug-induced hypotension 
In Table I the cases from the literature are summarized20-33# 
Cerebral ischaemia caused by hypotension is reported as side effect 
of all kinds of antihypertensive agents, both the powerful, like 
diazoxide, and more commonly used antihypertensive drugs such as 
ß-blocking drugs, diuretics, vasodilators and ACE inhibitors. 
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Graham^O was the first to describe two patients with ischaemic 
brain damage induced by a hypotensive period after starting bethani-
dine (a guanethidine derivative) and pentolinium (a qanqlion-blocking 
drug) treatment respectively. Post-mortem examination revealed 
ischaemic damage in the "border zone" (i.e. the area between the 
major arterial territories of the brain) implicating the hypotensive 
period as a likely cause of the brain damage. The importance of such 
pathological findings has been shown by Adams et al34; they found 
border zone lesions in patients after a precipitate reduction in 
systemic blood pressure, and more diffuse changes in patients with 
sustained hypotension. 
Jackson et al^l described б elderly patients with signs of cerebral 
ischaemia presented shortly after starting methyldopa (n=5) in a dose 
of 3 χ 250 mg daily and the p-blocker Oxprenolol (n=l). In the 
patient aged 84 years we calculated a fall in mean arterial blood 
pressure (MAP) of 11%. The others all showed a more marked fall in 
blood pressure. When treatment was stopped, blood pressure returned 
to pretreatment levels and the patients improved, although one had 
residual left-sided homonymous hemianopsia. 
Kumar et al.22 presented a patient with persistent right-sided 
hemiplegia after hypotension induced by diazoxide. Blood pressure 
fell from very high (290/160 mmHg) to an unrecordable level. Another 
patient described by these authors suffered myocardial infarction 
after diazoxide induced hypotension (not in the Table). 
Cove et al23 reported blindness in two young patients after a rapid 
fall in blood pressure as a consequence of vigorous treatment for 
malignant hypertension, in one with methyldopa 500 mq six-hourly and 
propranolol 80 mg eight-hourly, and in the other with a combination 
of diazoxide, furosemide and atenolol. The blindness was irreversible 
in both patients. 
Ledingham and Rajagopalan^^ described ten patients who developed 
neurological signs upon a rapid reduction of arterial pressure with 
the powerful antihypertensive drug diazoxide in nine cases (in eight 
combined with other antihypertensive agents) and a combination of 
hydralazine, amiloride and propranolol in one patient. Three died; 
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TABLE I. CASES OF CEREBRAL ISCHAEMIA DUE TO DRUG INDUCED HYPOTENSION (BPrBlood Pressure; 
ΔΜΑΡ-Change in mean arterial blood pressure; CHF=congestive heart failure) 
AUTHOR 
Graham (20) 
Jackson (21) 
et al. 
Kumar (22) 
et al. 
Cove (23) 
et al. 
AGE 
60 
35 
75 
71 
64 
68 
BA 
70 
63 
30 
32 
DRUG 
bethanidine 
pentoliniun 
methyldopa 
Oxprenolol 
cyclopenthiazide 
methyldopa 
cyclopenthiazide 
methyldopa 
cyclopenthiazide 
methyldopa 
methyldopa 
diazoxide 
methyldopa 
propranolol 
diazoxide 
furosemide 
atenolol 
SIGNS 
unconscious 
unconscious 
collapsed; confusion 
drowsiness; fainting 
collapsed; dizziness 
could not stand up 
blurred vision collapsed 
collapsed, nausea 
visual disturbance, 
unable to walk 
unconscious 
convulsions slurred 
speech 
collapsed, unable 
to walk 
collapsed, drowsy 
hemiplegia 
con fused 
blindness 
blindness 
FALL IN 
240/140 
240/170 
220/110 
210/120 
200/120 
1B0/100 
210/B0 
160/100 
290/160 
270/175 
250/170 
BP 
-• 
+ 
• > • 
- » • 
·¥ 
-• 
+ 
+ 
-V 
> 
120/85 
unrecord-
able 
130/80 
80/50 
140/90 
100/BO 
150/90 
100/70 
unrecord-
able 
100/50 
90/70 
ΔΜΑΡ 
(S) 
-44 
*? 
-34 
-40 
-27 
-32 
-11 
-33 
9 
-68 
-61 
Ledingham 60 
et al. (24) 
57 
30 
56 
64 
4B 
33 
56 
50 
34 
diazoxide 
propranolol 
furosemide 
diazoxide 
hydralazine 
diazoxide 
promazine 
diazoxide 
diazoxide 
reserpine 
chlorpromazine 
diazoxide 
methyldopa 
diazoxide 
hydralazine 
tnmetaphan 
hydralazine 
anilonde 
propranolol 
diazoxide 
hydralazine 
propranolol 
diazoxide 
hydralazine 
propranolol 
bethamdine 
prochloorperazine 
confused 
dysphaaic 
unconscious 
poor vision 
convulsion 
unconscious 
resp. arrest, after 
resuscitation 
choreo-athetosis 
unconscious 
cardiac arrest 
unconscious 
deceased 
unconscious 
hemiplegia 
drowsy 
disoriented 
weakness of l e f t 
side of face 
drowsy 
fixed and di lated 
pupils 
drowsy 
confusion 
240/155 + 130/90 -42 
220/155 -• 130/80 -45 
220/145 * 70/40 -71 
230/130 ·• BO/40 -67 
240/130 + 150/90 
300/160 •• 70/-
250/150 + 80/60 
210/150 ·• 130/B0 
-34 
-99 
-64 
-43 
210/170 + 120/75 -51 
250/140 -• 100/70 -55 
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the postmortem revealed areas of ischaemic damage in the brain. Four 
patients were left with some permanent neurological disability. Three 
patients recovered completely. 
Phillips and Jones^S described the death of a patient using 100 mg 
atenolol. Four hours after taking the first tablet he complained of 
dizziness and weakness; complete hemiplegia developed; blood pressure 
was markedly decreased as compared with pretreatment levels; he 
became unconscious and died a few hours later. 
Ruff et al.26 reported б patients developing transient ischaemic 
attacks (TIA) after a period of hypotension induced by antihyper­
tensive therapy. Three of these patients had severe carotid artery 
stenosis (the first three aged 69, 72 and 69 years in Table I). All 
had previously been hypertensive. 
Hodsman et al.27 described 6 hypertensive patients with signs of 
cerebral ischaemia (dizziness, dysphasia, hemiparesis, drowsiness, 
stupor) due to hypotension after the first dose of Captopril. The 
Captopril dose varied from 6.25 to 25 mg. After correction of blood 
pressure with infusions of anqiotensin II or saline the neurological 
signs resolved. 
Pitlik et al.28 reported loss of vision in the left eye induced by 
nifedipine in an elderly man after an oral dose of 20 mg. Vision 
improved within the next few hours. Six hours later he was rechal-
lenged with 20 mg nifedipine, resulting in a decrease in blood 
pressure and again loss of vision in the left eye. Treatment with 
nifedipine was stopped and the left visual field defect resolved 
completely. 
Haas et al. 29 described a 37 year old woman treated with 
propranolol and nitroprusside because of severe hypertension. Blood 
pressure fell precipitously; she developed visual disturbances, 
became lethargic and confused, and died after a few days. 
Strandgaard et al.^O reported two patients treated with a 
combination of furosemide and chlorpromazine, with visual distur­
bances after an acute fall in blood pressure. After correction of the 
hypotension the patients regained normal visual acuity. 
There are also reports on cerebral ischaemia, induced by hypotension, 
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TABLE I (continued) 
Phillipe (25) 
et al. 
Rufr (26) 
et al. 
Hodaman (27) 
et al. 
Pitlik (28) 
et al. 
Haas (29) 
et al. 
Strandgaard 
et al (30) 
Cleland (31) 
et al. 
50 
69 
72 
69 
81 
69 
73 
67 
55 
? 
7 
9 
7 
67 
37 
47 
61 
64 
54 
68 
atenolol 
diuretica 
and 
vasodilators 
methyldopa 
diuretica 
Captopril 
Captopril 
Captopril 
Captopril 
Captopril 
Captopril 
nifedipine 
propranolol 
nitroprusside 
furosemide 
chlorpromazine 
furosemide 
chlorpromazine 
Captopril 
for CHT 
Captopril 
for CHT 
Captopril 
for CHT 
hemiparesis 
deceased 
TIA 
TIA 
TIA 
TIA 
TIA 
TIA 
drowsiness 
dysphasic 
paresis left 
dizziness 
stupor 
drowsiness 
drowsiness 
blindness 
arm 
retinal ischemia 
fainting, Ы: indness 
lethargic, confused 
deceased 
visual impairment 
infarction 
visual 
impairment 
syncope 
syncope 
syncope 
240/140 
•7 
7 
7 
7 
7 
7 
222/12B 
206/132 
214/136 
144/102 
250/112 
186/120 
7 
220/120 
240/130 
180/100 
? 
7 
7 
• 
-» 
-V 
+ 
+ 
-» 
-> 
-* 
+ 
+ 
+ 
135/80 
7 
7 
7 
7 
7 
7 
48/44 
130/88 
76/58 
60/40 
90/58 
110/50 
110/70 
110/50 
180/90 
105/80 
-57 
-21 
-23 
-16 
-22 
-19 
-26 
-72 
-35 
-60 
-60 
-57 
-51 
7 
-54 
-32 
-30 
mean 
-46 
Cleland (32) 64 
et a l . 
61 
66 
enalapril 
for СНГ 
enalapril 
for СНГ 
enalapril 
for СНГ 
syncope 
faintness 
syncope 
-33 
-42 
-27 
as side effect of drugs not given because of hypertension; Cleland et 
al.31,32 described patients with signs of cerebral ischaemia after 
an initial small dose of Captopril (6.25 mg) and enalapril (5-10 mg) 
given because of heart failure. Especially patients with a high 
plasma renin activity may develop hypotension after captopril33# 
DISCUSSION 
Antihypertensive treatment has proved to reduce mortality and 
morbidity from cerebrovascular accidents^"!!. It is common clinical 
practice to start drug treatment in elderly hypertensive patients 
with a diastolic blood pressure of 115 mmHg or more, or with a 
diastolic pressure in the range 100-114 mmHg in the presence of 
complications or a systolic pressure greater than 180 rmiHglS.lö. 
However, it is still under discussion if and when the aged patient 
with milder hypertension and without organ damage should be treated. 
In any case, when deciding to start antihypertensive treatment in the 
elderly close attention must be given to side effects of antihyper-
tensive drugs. 
This review reports the cases from literature with cerebral damage 
possibly due to drug-induced hypotension. In the young such events 
occur only after a marked blood pressure reduction with powerful 
agents such as diazoxide or nitroprusside. Normally the cerebral 
autoregulation protects the brain against blood pressure fluctua-
tions; when blood pressure falls cerebral vessels dilate and when 
blood pressure rises they constrict,resulting in a constant cerebral 
blood flow in ranges of MAP from 60 to 150 mmHg in the young35; 
reduction of MAP by about 55Я causes symptoms of cerebral hypoperfu­
sion in this age group36. The finding of a pronounced shift upwards 
of the brain autoregulation curve in hypertensive patients signifies 
that blood pressure reduction must be gradual in these patients, 
because failure of autoregulation occurs at MAP levels higher than 60 
mmHg37. 
In the elderly signs of cerebral ischaemia may occur even after a 
rather small reduction in MAP. This may have several reasons. 
Firstly, in the aged the baroreflex is less sensitive, and a quick 
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Fig. 1. 
Druq-induced fall in MAP (%) as a possible cause of cerebral 
ischaemia or stroke vs aqe in the reported patients from Table 1. 
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fall in blood pressure cannot be compensated as promptly as in the 
younq38# Secondly, in the elderly the cerebral autoregul at i on may 
be impaired; Wollner et al.39 studied seven elderly patients with 
postural hypotension and symptoms of cerebral ischaemia; the patients 
turned out to have unilateral or bilateral failure of cerebral auto-
regulation. The fall in MAP after a change in posture varied from 8% 
to 37%; it was concluded that elderly patients with impaired cerebral 
autoregul at ion may be at risk of brain damage from minor falls in 
blood pressure. A third point of importance is a 25% reduction of 
cerebral blood flow in the aged as compared with the young^O. 
Finally, in the presence of carotid vascular disease even a small re-
duction in blood pressure may cause cerebral ischaemia, as shown in a 
study by Ruff et al.26. 
For all these reasons the elderly are especially at risk of develop-
ing cerebral ischaemia after a quick and marked fall in blood pres-
sure: in this age group a reduction of MAP by far less than 55% can 
already induce cerebral ischaemia. This may be illustrated by Fig. 1 
in which the fall in MAP and the age of the patients from Table I are 
put together (only patients of known age and with a known fall in MAP 
are represented in this figure). 
Fortunately, not every elderly patient is at risk of developing cere-
bral ischaemia after blood pressure reduction; when autoregul at i on is 
not impaired, the carotid arteries are patent and cerebral blood flow 
and baroreflex sensitivity are only slightly diminished, a fall in 
MAP by less than 30-40* would probably not induce cerebral ischae-
mia. Because in general practice it is not possible to study these 
parameters in every elderly patient with hypertension, it is advisa-
ble to start antihypertensive treatment in small doses, aiming at a 
gradual reduction of blood pressure. 
36 
REFERENCES 
I. Kannel WB, Wolf PA, Verter J, and McNamara PM. Epidemiologic 
assessment of the role of blood pressure in stroke: The 
Framingham Study. JAMA 1970; 214 : 301-10. 
?.. Shekelle RB, Ostfeld AM, and Klawans HL. Hypertension and risk of 
stroke in an elderly population. Stroke 1974; 5 : 71-5. 
3. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, and Castelli 
WP. Systolic blood pressure, arterial rigidity, and risk of 
stroke. The Framingham Study. JAMA 1981; 245 : 1225-9. 
4. Forette F, de la Fuente X, Golmard J-L, Henry J-F, and Hervy M-P. 
The prognostic significance of isolated systolic hypertension in 
the elderly. Results of a ten year longitudinal survey. Clin Exp 
Hyp 1982; (A4)7 : 1177-91. 
5. Colandrea MA, Friedman GD, Nichaman MZ, and Lynd CN. Systolic 
hypertension in the elderly. An epidemiological assessment. 
Circulation 1970; 41 : 239-45. 
6. Amery A, Birkenhäger W, Brixko Ρ et al. Mortality and morbidity 
results from the European Working Party on high blood pressure in 
the elderly trial. Lancet 1985; I : 1349-54. 
7. Veterans Administration Cooperative Study Group on Antihyperten­
sive Agents. Effects of treatment on morbidity in hypertension. 
III. Influence of age, diastolic pressure and prior cardiovascu­
lar disease; further analysis of side effects. Circulation 1972; 
45 : 991-1004. 
8. Hypertension Detection and Follow-up Program Cooperative Group. 
Five year findings of the hypertension detection and follow-up 
program. II. Mortality by race-sex and age. JAMA 1979; 242 : 
2572-7. 
9. Report by the Management Committee. The Australian therapeutic 
trial in mild hypertension. Lancet 1980; I : 1261-7. 
10. Beevers DG, Fairman MJ, Hamilton M, and Harpur JE. Antihyperten­
sive treatment and the course of established cerebrovascular 
disease. Lancet 1973; I : 1407-9. 
II. Marshall J. A trial of long-term hypotensive therapy in cerebro­
vascular disease. Lancet 1964; I : 10-2. 
37 
12. Hypertension-Stroke Cooperative Study Group. Effect of antihyper­
tensive treatment on stroke recurrence. JAMA 1974; 229 : 409-18. 
13. Carter AB. Hypertensive therapy in stroke survivors. Lancet 1970; 
I : 485-9. 
14. WHO. Report of a WHO Exp Committee. Arterial hypertension. WHO 
Techn Rep Ser 1978; 628. 
15. Franklin SS. Geriatric Hypertension, in: Samiy AH (ed) Clinical 
Geriatric Medicine, Med Clin of N Am, W.B. Saunders, Philadelphia 
1983; 395-417. 
16. O'Callaghan W, O'Brien E, O'Malley K. Hypertension in the elder­
ly: epidemiology, pathophysiology and management in: O'Malley К 
(ed) Clinical Pharmacology and drug treatment in the elderly, 
Churchill Livingstone, Edinburgh 1984; 122-138. 
17. Hurwitz H. Predisposing factors in adverse reactions to drugs. 
Br Med J 1969; I : 536-9. 
18. Ouslander JG. Drug therapy in the elderly. Ann Int Med 1981; 95 : 
711-22. 
19. Jansen PAF, Meyboom RHB, Schulte BPM, and Gribnau FWJ. Antihyper­
tensive treatment as a possible cause of stroke in the elderly. 
Age Ageing 1986; 15 : 129-38. 
20. Graham 01. Ischaemic brain damage of cerebral perfusion failure 
type after treatment of severe hypertension. Br Med J 1975; IV : 
739. 
21. Jackson G, Mahon W, Pierscianowski ТА, and Condon J. Inappro­
priate antihypertensive therapy in the elderly. Lancet 1976; II : 
1317-8. 
22. Kumar GK, Dastoor FC, Robayo JR, and Razzaque MA. Side effects of 
diazoxide. JAMA 1976; 235 : 275-6. 
23. Cove OH, Seddon M, Fletcher RF, and Dukes DC. Blindness after 
treatment for malignant hypertension. Br Med J 1979; II : 245-6. 
24. Ledingham JGG, and Rajagopalan B. Cerebral complications in the 
treatment of accelerated hypertension. Q J Med 1979; 48 : 25-41. 
25. Phillips MS, and Jones JV. Emergency treatment of high blood 
pressure with oral atenolol. (Letter) Br Med J 1981; 283 : 58. 
38 
26. Ruff RL, Taiman WT, and Petito F. Transient ischaemic attacks 
associated with hypotension in hypertensive patients with carotid 
artery stenosis. Stroke 1981; 12 : 353-5. 
27. Hodsman GP, Isles CG, Murray GO, Usherwood TP, Webb OJ, and 
Robertson JIS. Factors related to first dose hypotensive effect 
of Captopril: prediction and treatment. Br Med J 1983; 286 : 
832-4. 
28. Pitlik S, Manor RS, Lipshitz I, Perry G, and Rosenfeld J. 
Transient retinal ischaemia induced by nifedipine. Br Med J 1983; 
287 : 1845-6. 
29. Haas DC, Streeten DHP, Kim RC, Naalbandian AN, and Obeid AI. 
Death from cerebral hypoperfusion during nitroprusside treatment 
of acute anqiotensin-dependent hypertension. Am J Med 1983; 75 : 
1071-6. 
30. Strandqaard S, Andersen GS, Ahlqreen P, and Nielsen PE. Visual 
disturbances and occipital brain Infarct following acute, 
transient hypotension in hypertensive patients. Acta Med Scand 
1984; 216 : 417-22. 
31. Cleland J, Semple P, Hodsman P, Ball S, Ford I, and Dargie H. 
Anqiotensin II levels, hemodynamics, and sympathoadrenal function 
after low-dose Captopril in heart failure. Am J Med 1984; 77 : 
880-6. 
32. Cleland JGF, Dargie HJ, McAlpine H et al. Severe hypotension 
after first dose of enalapril in heart failure. Br Med J 1985; 
291 : 1309-12. 
33. Labarre TR, O'Conneli JB, Gunnar RM. Captopril therapy for severe 
CHF: hypotensive response in presence of markedly elevated PRA. 
(Letter) Am Heart J 1982; 103 : 308-10. 
34. Adams JH, Brierley B, Connor RCR, and Treip CS. The effects of 
systemic hypotension upon the human brain, clinical and neuro-
pathological observations in 11 cases. Brain 1966; 89 : 235-80. 
35. Johnson RH, Lambie DG, and Spalding JMK (eds) Neurocardiology. 
The interrelationship between dysfunction in the nervous and 
cardiovascular systems. WB Saunders, London 1984; 261-322. 
39 
36. Strandgaard S. Autoregulation of cerebral blood flow in hyper-
tensive patients. The modifying influence of prolonged antihyper-
tensive treatment on the tolerance to acute, drug-induced hypo-
tension. Circulation 1976; 53 : 720-7. 
37. Strandgaard S, Olesen J, Skinhej E, Lassen NA. Autoregulation of 
brain circulation in severe arterial hyoertension. Br Med J 1973; 
I : 507-510. 
38. Giibbin B, Pickering TG, Sleight P, and Peto R. Effect of age and 
high blood pressure on baroreflex sensitivity in man. Circulation 
Res 1971; 29 : 424-31. 
39. Wollner L, McCarthy SI, Soper NOW, and Macy DJ. Failure of 
cerebral autorequlation as a cause of brain dysfunction in the 
elderly. Br Med J 1979; I : 1117-8. 
40. Davis SM, Ackerman RH, Correia JA et al. Cerebral blood flow and 
cerebrovascular COj reactivity in stroke-age normal controls. 
Neurology 1983; 33 : 391-9. 
40 
CHAPTER 4 
ANTIHYPERTENSIVE TREATMENT AS A POSSIBLE 
CAUSE OF STROKE IN THE ELDERLY 
P.A.F. Jansen, B.P.M. Schulte, R.H.B. Meyboom, F.W.J. Gribnau 
published in 
Age and Ageing 1986; 15 : 129-138 
SUMMARY 
There have been a few reports on stroke as a side-effect of anti-
hypertensive treatment. To study the occurence of this side-effect, a 
questionnaire was sent to all Dutch nursing homes (n=322). Thirty 
patients were reported with signs of cerebral ischaemia shortly after 
starting antihypertensive and diuretic drugs. Nine of these cases 
were well documented with full data on blood pressure, measured 
immediately after the event and compared with pretreatment levels. 
A review of cases reported in the literature is presented. 
It is concluded that, especially in elderly patients, an abrupt fall 
in blood pressure may induce cerebral ischaemia, sometimes resulting 
in stroke. Antihypertensive treatment in the elderly should therefore 
start with a small dose, the aim being to reduce blood pressure 
gradually. 
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INTRODUCTION 
The beneficial effects of antihypertensive treatment in the preven-
tion of stroke are well established. Among the side-effects of the 
drugs used for this indication, reports in the literature paradoxi-
cally mention signs of cerebral ischaemia, stroke and visual impair-
mentl"13. in an attempt to gather information on the extent of the 
problem of antihypertensive or diuretic treatment as a contributing 
factor to cerebral ischaemia or stroke, a questionnaire was sent to 
all Dutch nursing homes, as it was assumed that the type of patients 
concerned might be found within the population of nursing-home 
patients. 
MATFRIALS AND METHODS 
A questionnaire was sent to all medical directors of Dutch nursing 
homes (n=322). The following questions were posed: 
- Do you know of patients suffering from (ir)reversible focal cere-
bral deficit, presented shortly after starting medication with 
furosemide; 
- other diuretics 
- beta-blocking drugs 
- vasodilators 
- methyldopa 
- others 
- combinations 
- If so, is the patient 
- under your treatment 
- discharged 
- deceased 
Stroke is defined as rapidly developing clinical signs of focal dis-
turbance of cerebral function lasting more than 24 hours or leading 
to death, with no apparent cause other than a vascular origin, as 
used by the WHO14. 
The term 'signs of cerebral ischaemia' is used for all clinical symp-
toms apparently due to impaired cerebral perfusion, reversible within 
24 hours. 
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erom the reported cases all available data were collected by way of 
correspondence or telephone. From this information, the interval 
between the start of antihypertensive or diuretic treatment and the 
development of signs of cerebral ischaemia or stroke was noted. The 
difference in blood pressure measured before treatment and directly 
after stroke (or during cerebral ischaemia), was expressed as change 
in mean arterial pressure (ΔΜΑΡ) and calculated according to the 
equation: 
MAP = diastolic pressure + 1/3 (systolic-diastolic pressure) 
дмдр = MAP after stroke - MAP before treatmentxinog 
MAP before treatment 
RESULTS 
The questionnaire was completed and returned by 177 (55%) physicians, 
of whom 25 reported 30 patients with signs of cerebral ischaemia or 
stroke developing within two weeks of the start of antihypertensive 
or diuretic treatment (Table I). Twenty-two patients suffered a 
stroke; the other eight patients showed signs of cerebral ischaemia: 
drowsiness, dizziness, collapse, and in one a seizure of vascular 
origin occurred. Nine patients were still in the nursing home, nine 
TABLE I 
30 REPORTED CASES WITH SIGNS OF CEREBRAL ISCHAEMIA OR STROKE WITHIN 
TWO WEEKS OF THE START OF ANTIHYPERTENSIVE OR DIURETIC TREATMENT 
medication indication 
η signs 
furosemide 
furosemide 
furosemide 
methyldopa 
Dyta-ureseR 
mefruside 
metoprolol 
atenolol 
labetalol 
prazosin 
Clonidine 
heart failure 
hypertension 
renal insufficiency 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
9 
2 
1 
9 
3 
1 
1 
1 
1 
1 
1 
stroke(7) ischaemia(2) 
stroke(l) ischaemia(l) 
stroke 
stroke(9) 
ischaemia(3) 
stroke 
stroke 
ischaemia 
stroke 
stroke 
ischaemia 
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TABLE II. DATA AND BLOOD PRESSURE (BP; mmHg) COURSE IN 9 PATIENTS (F = female, M = male) 
AGE(yr) MEDICATION NEWLY INSTALLED INDICATION BP BEFORE 
gender DRUG (SINCE) TREATMENT 
BP AFTER STROKE 
OR DURING ISCHEMIA 
AMAP SIGNS COURSE 
77 
F 
67 
F 
76 
F 
79 
M 
74 
M 
71 
M 
73 
M 
Θ5 
M 
75 
M 
Dyta-urese' 
Indapamide 
methyldopa 
metoprolol 
furoaemide 
Dytenzide" 
metoprolol 
-
-
(hours) 
2 χ 250 mg 
labetalol 
(2 days) 
3 χ 200 mg 
prazosin 
(hours) 
2 χ 0.5 mg 
Furosemide 
(7 days) 
1 χ 40 mg 
metoprolol 
(hours) 
1 dd 100 mg 
mefruside 
(12 days) 
1 χ 25 mg 
atenolol 
(2 days) 
1 χ 100 mg 
furoaemide 
(2 days) 
200 mg total 
methyldopa 
(7 days) 
2 χ 250 mg 
and Dyta-Urese" 
(7 days) 1 χ 1 
hypertension 230/120 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
heart failure 
hypertension 
210/120 
240/130 
210/130 
240/130 
200/120 
220/120 
240/140 
190/120 
190/100 
160/80 
190/80 
140/90 
150/90 
110/80 
130/70 
120/65 
60/60 
-17» 
-29?! 
-30Ä 
-323 
-34S 
-36Я 
-415 
-52Ä 
-53S 
cerebellar 
infarction 
hemispheric 
infarction 
hemispheric 
infarction 
drowsy 
fainting 
hemispheric 
infarction 
hemispheric 
infarction 
confusion 
collapse 
hemispheric 
infarction 
hemispheric 
infarction 
partly recovered 
after cessation of 
Dyta-UreseR and 
methyldopa 
no recovery 
no recovery 
recovery 
after cessation 
of furosemide 
recovery after 
cessation 
metoprolol 
partly recover-
ed after cessa-
tion mefruside 
recovery after 
cessation 
atenolol 
no recovery 
no recovery 
had been discharged and twelve had died. Personal data (sex, age) 
were not available in nine cases. The other 21 were 12 women and 
9 men with a mean age of 77.6±8.4 years. 
Detailed data on the course of blood pressure were available on 8 
patients with antihypertensive treatment and one receiving a loop 
diuretic because of heart failure (Table II). 
The patient aged 77, started with Dyta-Urese^ for hypertension. 
Rlood pressure was measured after a few days of treatment and 
although signs of cerebral ischaemia were present (fainting), methyl-
dopa was added and stroke occurred. At that time no blood pressure 
figures were recorded. In six patients who were already using anti-
hypertensive medication, the event occurred shortly after addition of 
one more antihypertensive drug. 
All these patients had severe hypertension. Pretreatment systolic 
pressure ranged from 190 to 240 (mean 220)mmHg and diastolic pres-
sure from 120 to 140 (mean 126)mmHg. The systolic pressure first-
recorded during signs of cerebral ischaemia or after stroke ranged 
from 80 to 190 (mean 141)mmHg and diastolic pressure from 60 to 100 
(mean 79) mmHg. The fall in MAP varied from 17 to 53%. There was 
partial or complete recovery after cessation of therapy in five of 
the nine patients. 
DISCUSSION 
High blood pressure is a powerful contributor to cardio- and cerebro-
vascular diseasel5-18f in the elderly alsol9-21# Several studies 
have shown that antihypertensive treatment reduces mortality and mor-
bidity22-25# However, there is no consensus about the level above 
which antihypertensive treatment should be started. The most widely 
accepted definition of hypertension, that of the WHO, is a systolic 
pressure of 160 mmHg or higher and/or a diastolic pressure of 95 mmHg 
or higher^. However, this definition does not take age into 
account. In the study of the European Working Party on High Blood 
Pressure in the Elderly, treatment was started above 160 mmHg systo-
lic and 90 tmiHg diastolic^, others have defined ranges for treat-
ment of elderly hypertensives: a diastolic pressure of 100-110 mmHg 
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110 mmHg in the presence of complications or a systolic pressure 
above 180 mmHg27. There is general agreement that a diastolic blood 
pressure above 115 mmHg requires treatment in any age category.It is 
of course no matter of discussion that the patients described in 
Table II needed antihypertensive treatment. 
In the elderly especially, hypertension should be treated with 
caution for several reasons. Firstly, in the aged the baroreflex is 
less sensitive, and a quick fall in blood pressure cannot be compen-
sated immediately as in the young28# 
A second point of importance is cerebral autorequlation. The brain 
is protected against blood pressure fluctuations by autoregulation. 
When blood pressure falls, cerebral vessels dilate; when blood 
pressure rises, they constrict, resulting in a constant cerebral 
blood flow in MAP ranges from 60 to 150 mmHg in normal individuals. 
The brain of a patient with chronic hypertension is more vulnerable 
to hypotension because the cerebral autoregulatory curve shifts 
upwards: in these patients a reduction of cerebral blood flow occurs 
at a higher MAP than in normotensives^. A reduction in MAP of 
about 25% is required to reach the lower limit of cerebral blood flow 
autorequlation; a further reduction to about 55% is needed to cause 
symptoms of brain hypoperfusion in both hypertensive and normotensive 
subjects under the age of 66 years^O. in the elderly - even in the 
absence of hypertension - cerebral autoregulation can be impair-
ed31. 
In the early 1950s an inverse correlation was demonstrated between 
cerebral blood flow oer se and age with a reduction of about 25% in 
the aged as compared with the young32. in later years this finding 
was confirmed by other authors using more modern methods^,34. 
Another important factor in cerebral blood flow is the haematocrit: 
flow is lower with a high haematocrit (over 0.46)35. However, 
regulatory mechanisms can maintain normal cerebral oxygen transport 
despite increased plasma and whole blood viscosity36. 
It might have been expected that atherosclerosis would be an impor-
tant factor in lowering the flexibility of brain arteries, patients 
with the most pronounced arteriosclerosis being the most endangered 
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for stroke in the event of a hypotensive episode. Several studies, 
however, do not support this concept37,38# Torvik and Skullerud 
studied 115 cases with cardiac arrest and found no correlation be­
tween the degree of arteriosclerosis and the risk for brain infarcts 
as a complication of the hypotensive episode^. A relationship be­
tween the morphological substrate and the outcome of a period of 
hypotension does exist, as shown by the neuropathological observa­
tions of Adams et al. in 11 patients39; the necrosis of grey and 
white matter at the boundary zones ("watersheds") appeared to be at­
tributable to a precipitous reduction in systemic blood pressure, 
while diffuse alterations seemed to be the result of a moderate but 
sustained systemic hypotension. 
In a retrospective study of post-mortems, fatal strokes in elderly 
patients often appeared to be due to acute hypotension caused by 
events such as heart failure, occult haemorrhage, or multiple pulmo­
nary embolismi^. 
There are several reports in the literature of cerebral ischaemia, 
stroke and visual impairment as side effects of antihypertensive 
treatment; these reports are listed in Table III. 
TABLE III. CASES OF CEREBRAL ISCHAEMIA OR STROKE, INDUCED BY HYPOTENSION, FROM THE 
LITERATURE 
AUTHOR 
Grahan ( 1 ) 
Jackson ( 2 ) 
et a l . 
AGE 
60 
35 
75 
71 
64 
68 
84 
70 
DRUG 
b e t h a m d i n e 
p e n t o l i m u n 
methyldopa 
Oxprenolol 
c y c l o p e n t h i a z i d e 
methyldopa 
c y c l o p e n t h i a z 
methyldopa 
i d e 
c y c l o p e n t h i a z i d e 
methyldopa 
methyldopa 
SIGNS 
unconscious 
unconscious 
c o l l a p s e d ; confusion 
drowsiness; f a i n t i n g 
c o l l a p s e d ; d i z z i n e s s 
could not stand up 
b l u r r e d v i s i o n c o l l a p s e d 
c o l l a p s e d , nausea 
v i s u a l d i s t u r b a n c e , 
unable to v a l k 
unconscious 
convulsions s l u r r e d 
speech 
c o l l a p s e d , unable 
to walk 
c o l l a p s e d , drowsy 
FALL IN 
240/140 
240/170 
2 2 0 / 1 1 0 
210/120 
2 0 0 / 1 2 0 
1 8 0 / 1 0 0 
210/80 
160/100 
BP 
+ 
* 
+ 
• » 
* 
* 
·¥ 
·* 
120/85 
unrecord-
a b l e 
130/80 
80/50 
140/90 
100/80 
150/90 
100/70 
ΔΜΑΡ 
-44% 
7 
-34S 
-40S 
-27S 
-32S 
- I I S 
-33S 
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Cove (4) 
et al. 
Ledingham 
et al. (5) 
Pitlik CS) 
et al. 
Phillips 
et al. (7) 
Strandgaard 
et al tB) 
Kumar (9) 
et al. 
Haas (10) 
et al. 
30 
32 
60 
57 
30 
56 
64 
4Θ 
33 
56 
50 
34 
67 
50 
47 
61 
63 
37 
methyldopa 
diazoxide 
furoaemide 
atenolol 
diazoxide 
propranolol 
furosemide 
diazoxide 
hydralazine 
diazoxide 
promazine 
diazoxide 
diazoxide 
reserpine 
chlorpromazine 
diazoxide 
methyldopa 
diazoxide 
hydralazine 
tnmetaphan 
hydralazine 
amiloride 
propranolol 
diazoxide 
hydralazine 
propranolol 
diazoxide 
hydralazine 
propranolol 
bethanidine 
prochloorperazine 
nifedipine 
atenolol 
furosemide 
chioorpromazine 
furosemide 
chloorpromazine 
diazoxide 
propranolol 
nitroprusside 
confused 
blindness 
blindness 
confused 
dysphasic 
unconscious 
poor vision 
convulsion 
unconscious 
reep. arrest, 
resuscitation 
athetosis 
unconscious 
cardiac arres 
unconscious 
deceased 
unconscious 
hemiplegia 
drowsy 
disoriented 
sfter 
choreo-
t 
makness of left 
side of face 
drowsy 
fixed and dilated 
pupils 
drowsy 
confusion 
blindness 
retinsl ischaemia 
hemiparesis 
deceased 
visual impairment 
infarction 
visual 
impairment 
hemiplegia 
fainting, blindness 
lethargic, cor 
deceased 
ι fused 
270/175 + 100/50 
250/170 + 90/70 
240/155 + 130/90 
220/155 •• 130/80 
220/145 + 70/40 
230/130 * BO/40 
240/130 -• 150/90 
300/160 ·<· 70/-
250/150 * BO/60 
210/150 + 130/B0 
210/170 - 120/75 
250/140 + 100/70 
? •• 110/70 
240/140 - 135/BO 
240/130 * 1 BO/90 
180/100 + 105/80 
290/160 - 230/130 
220/120 • 110/50 
-685 
-61S 
-42S 
-45S 
-71S 
-67S 
-34S 
-B9ÎS 
-64Х 
-43S 
-51» 
-55S 
? 
-575 
-32S 
-30S 
-205 
-545 
Coppeto (11) 78 timolol ocgtt. visual impairment ? •» 135/60 
Δ MAP (%) 
-100-
-80-
-60-
-40 
-20 
20 40 60 80 100 
Age (уг) 
Fig. 1. 
Relationship between fall in MAP after start of antihypertensive/ 
diuretic treatment (resulting in signs of cerebral ischaemia or 
stroke) and age of 9 patients presented in this paper (open circles) 
and 24 patients reported in the literature (solid circles). 
The Figure shows the ΔΜΑΡ values from this selection of the litera­
ture and from our patients, as described in Table II. They illustrate 
the greater vulnerability of the brain with increasing age. The pre­
sent data are in agreement with the findings of others that all kinds 
of antihypertensive or diuretic drugs may contribute to the develop­
ment of cerebral ischaemia or even stroke when blood pressure is 
lowered too quickly. The conclusion of our study, based on a small 
collection of epidemiological data, needs further substantiation. In 
this study we were unable to obtain information about the number of 
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inappropriately treated patients, who did not develop symptoms. In 
another study we collected data on 100 patients admitted for stroke 
in a community hospital, with particular reference to changes in 
blood pressure and on recent medication history. 
It is advisable to start antihypertensive treatment, especially in 
the elderly, with a small dose; the aim being to reduce blood pres-
sure gradually. Drugs like the high-ceiling loop diuretic furosemide 
are best avoided in the treatment of hypertension, because of their 
powerful hypovolaemic action with the risk of a quick fall of blood 
pressure. In the treatment of heart failure with furosemide, blood 
pressure control is needed. 
In conclusion, when starting antihypertensive treatment in the aged 
one should be aware that inaccurate, i.e. too quick or too marked,re-
duction of blood pressure may induce stroke. We therefore advocate a 
cautious approach in the treatment of high blood pressure, with 
appropriate drugs, especially in the elderly. 
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CASE HISTORIES 
Case I 
A woman aged 77 years, with known hypertension, atrial fibrillation 
and heart failure, was treated with Dyta-Urese·* one capsule daily, 
resulting in weight loss from 87 to 80 kg in a few days and a fall in 
blood pressure from 230/120 to 190/100 mmHg. In view of a propensity 
to collapse she was admitted to hospital. Methyldopa (2x250 mg) was 
added to the therapy and thereupon the patient suffered from distur-
bances of equilibrium and became aphasie. Blood pressure was not 
recorded at that time. A cerebral CAT-scanning showed cerebellar 
infarction. After 6 weeks the patient was transferred to a nursing 
home. She was drowsy and aphasie. Blood pressure was 120/80 mmHg and 
blood urea was 27.4 mnol/l. After the cessation of Dyta-urese" and 
methyldopa the blood pressure rose to 170/105 mmHg and the blood urea 
decreased to 5.1 mmol/1 (in the normal range). The patient improved: 
the neurological disturbances (vertigo, ataxia and aphasia) persist-
ed. 
Case II 
A woman aged 67 years used Indapamide once daily for two weeks 
because of recently detected hypertension (earlier blood pressure 
level 170/90 mmHg). A blood pressure of 210/120 mmHg was recorded and 
labetalol (3x200 mg) was added to the treatment. After 2 days the 
patient developed stroke and was admitted to hospital. Rlood pressure 
at admission was 160/80 mmHg. An infarction in the area of the right 
middle cerebral artery was diagnosed. After a few weeks she was 
transferred to a nursing hon». There was no recovery from the left-
sided hemiparesis. 
Case III 
A woman aged 76 years had been treated for hypertension over a long 
period; last treatment consisted of a combination of metoprolol, 
methyldopa and furosemide. Nevertheless, blood pressure was still 
high (240/130 imiHg) and prazosin 0.5 mg twice daily was added to the 
treatment. On the same day the patient developed left-sided hemipare-
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sis. At admission the blood pressure was 190/80 irniHg. Cerebral CAT-
scanning showed an infarction in the area of the right middle cere­
bral artery. Prazosin, methyldopa and metoprolol were stopped. The 
patient was transferred to a nursing home. There was no recovery from 
the hemiparesis. 
Case IV 
A man aged 79 years with known hypertension and mild diabetes melli­
tus had in the past been treated for congestive heart failure; this 
treatment had been stopped. Because of high blood pressure (210/ 
130 mmHg) the patient was treated with furosemide 40 mg once daily. 
After 7 days of treatment he became drowsy and was fainting. The 
blood pressure was 140/90 mmHg. Haemoglobin was 11.6 mmol Л , blood 
urea 16.2 mmol/1, blood glucose 11.1 mmol/l. After cessation of 
furosemide the patient recovered completely. 
Case V 
A woman aged 74 years with known moderate renal insufficiency (serum 
creatinine 146 μΐηοΐ/ΐ), was treated with DytenzideR because of 
hypertension. The blood pressure was 240/130 mmHg and metoprolol 
100 mg once daily was added to the therapy. Within 24 hours she 
became aphasie. The blood pressure was 150/90 mmHg. After cessation 
of metoprolol she recovered completely. 
Case VI 
A man aged 71 years had been treated for hypertension with metoprolol 
100 mg thrice daily during 1 year. Because of a blood pressure of 
200/120 mmHg, mefruside 25 mg once daily was started. After 12 days 
of treatment the patient awoke with right-sided hemiparesis. At 
admission the blood pressure was 110/80 mmHg. An infarction of the 
left frontolateral area was diagnosed. After cessation of mefruside 
the patient partly recovered. 
Case VII 
A man aged 73 years with known partial right-sided hemiparesis and 
57 
aphasia was treated with atenolol, 100 mg once daily, because of 
hypertension (220/120 mmHq). After 2 days the patient became confused 
and collapsed. The blood pressure was 130/70 mmHg and the heart rate 
50 beats/min. There was no exacerbation of the oartial hemiparesis. 
After cessation of atenolol the blood pressure rose and the new signs 
of cerebral ischaemia disappeared. 
Case VIII 
A man aged 85 years with known slight paresis of the right arm, 
atherosclerosis, non-insulin-dependent diabetes mellitus and myo-
cardial infarction was treated with furosemide 40 mg i.m. because of 
heart failure with severe dyspnoea. The blood pressure at that time 
was 240/140 mmHg. Because he remained dyspnoeic, 60 mq furosemide, 
240 mg aminophylline and 10 mg nicomorphine hydrochloride were given 
intravenously after 1 h. The patient improved and a blood pressure of 
190/105 mmHg was measured. Treatment with furosemide, 40 mg orally 
per day, was continued. After 2 days, complete paresis of the right 
arm developed. The blood pressure was 120/65 mmHg. It was thought 
necessary to continue furosemide medication. There was no recovery 
from the paresis. 
Case IX 
A man aged 75 years suffered from dizziness and extrapyramidal 
symptoms. He was admitted to hospital and normal pressure hydrocepha-
lus was diagnosed. Because of hypertension (190/120 mmHg) treatment 
was started with methyldopa, 250 mg twice daily, and Dyta-ureseR 
once daily, resulting in a fall in blood pressure to 135/85 mmHg. The 
patient was discharged, but within 7 days he became drowsy and 
developed disturbances of gait. He was readmitted with right-sided 
hemiparesis. The blood pressure at the time was 80/60 mmHq. Cerebral 
CAT-scanning showed an infarction in the area of the left middle 
cerebral artery. A blood urea of 42 mmol/1 was measured. After cessa-
tion of methyldopa and Dyta-urese^, the blood pressure rose to 135/ 
95 mmHg and the blood urea was nearly normalized at 10 mmol/1. The 
neurological changes proved to be irreversible. 
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CHAPTER 5 
CONTRIBUTION OF INAPPROPRIATE TREATMENT 
FOR HYPERTENSION TO PATHOGENESIS OF 
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ABSTRACT 
One hundred and seventy eight patients admitted to hospital with 
acute cerebral infarction or transient ischaemic attack were studied 
as to determine if their treatment had been changed during the 
previous three weeks and to compare their blood pressure after the 
stroke with premorbid values. Blood pressure measurements taken with-
in one year before the stroke were available for 100 patients; seven 
of these had had a recent change in antihypertensive or diuretic 
treatment. Of these, three patients who had started taking furosemide 
because of hypertension and one whose dosage of a reserpine combina-
tion drug had been increased experienced an appreciable decrease in 
blood pressure immediately after the stroke; they also showed signs 
of haemoconcentration. The change in treatment probably contributed 
to the stroke in these four patients. The other three showed a 
smaller decrease or even an increase of blood pressure and no signs 
of haemoconcentration; the relation between the change in treatment 
and stroke is less likely in these patients. 
The use of high ceiling diuretics such as furosemide in the treatment 
of hypertension may induce hypovolaemia and hypotension, resulting in 
cerebral ischaemia, and are therefore best avoided in such treatment. 
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INTRODUCTION 
Increased blood pressure, especially systolic hypertension, is 
associated with an increased risk of stroke in persons over the age 
of 60l~5. Other studies, including one by the European Working 
Party on High Blood Pressure in the Elderly, have shown that treat-
ment for hypertension in the elderly reduces cardiovascular and cere-
brovascular mortality and morbidityß"^, particularly non-fatal 
cerebrovascular events^. Treatment for hypertension may prevent the 
recurrence of strokelO'H, especially cerebral haemorrhage^, but 
this effect in the elderly is less certainl3-14# Nevertheless, 
treatment for hypertension in the elderly should be considered, 
though there is no consensus about the diastolic or systolic pressure 
above which treatment should be given. 
Stroke as paradoxical side effect of treatment for hypertension has 
been reported!*»^, vie previously sent a questionnaire to all 
medical directors of Dutch nursing homes (n=322), asking for informa-
tion on patients who suffered a stroke shortly after the start of 
antihypertensive or diuretic treatment. Thirty patients were report-
ed23; of these, complete blood pressure measurements were available 
for nine of them. They had all had an appreciable decrease in blood 
pressure immediately after the stroke. To establish whether inappro-
priate antihypertensive or excessively drastic diuretic treatment 
causes such events, and if so how often, we studied patients admitted 
to hospital with transient ischaemic attack or acute cerebral infarc-
tion to determine if there had been any change in treatment during 
the three weeks preceding admission and to measure blood pressure 
immediately after the event and compare it with premorbid values. 
PATIENTS AND METHODS 
We studied 178 consecutive patients with cerebral infarction or 
transient ischaemic attack admitted to the neurology department of a 
community hospital. In the emergency department a medical history was 
taken, including drugs being taken, and a standard physical and 
neurological examination was performed. Blood pressure was measured 
with a shpygmomanometer, and an electrocardiogram was recorded. Blood 
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was collected for measuring among others, potassium concentration, 
and haematocrit. In the neurology department, blood pressure was 
measured again, also with a sphygmomanometer and a computerised 
tomography scan was performed to distinguish between infarction and 
haemorrhage. When infarction or transient ischaemic attack was 
diagnosed by a neurologist according to the World Health Organisation 
criteria^*, information on the patient's medical history was 
collected. The patient's general practitioner was asked by telephone 
for premorbid blood pressure values; he was also asked about any 
change in the patient's treatment during the three weeks before the 
event, and about the medical history, especially hypertension, 
diabetes mellitus and vascular disease. If no blood pressure data 
were available for the past year the patient was excluded from the 
study. Eventually a series of 100 patients remained in whom the 
percentage change in mean arterial blood pressure after the stroke 
(ΔΜΑΡ) was determined from the following equation: 
МАРд-МАРв , _ 
ΔΜΑΡ = χ 100* 
MAP β 
where МАРд = mean arterial pressure after the stroke (mean of the 
two measurements taken in the emergency and neurology departments) 
and ΜΑΡβ = last arterial pressure measured by the general practi­
tioner before the stroke. In both cases mean arterial pressure was 
defined as the diastolic pressure plus one third of the difference 
between the systolic and diastolic pressures. 
RESULTS 
In 100 patients blood pressure had been measured within one year 
before admission (mean five months; range two days to one year). 
Table I shows the clinical and laboratory data on these patients.Of 
the 47 patients known to by their doctors to suffer from hypertension 
according to the criteria of the WHO 2 5, 38 (81%) were receiving 
treatment. Two of the 23 patients with diabetes mellitus were 
dependent on insulin. Of all the 100 patients, 21 had a haematocrit 
value greater than 0.46 (range 0.46-0.56). 
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TABLE I 
CLINICAL AND LABORATORY DATA (mean +SD) ON THE 100 PATIENTS 
sex and age 
women 
men 
age (yrs) 
range 
60 
40 
74.1+8.5 
51-91 
medical history 
- hypertension 47 
- diabetes mellitus 23 
- myocardial infarction 8 
- anqina pectoris 7 
- carotid artery pathology 5 
- stroke (previous) 5 
- hyperlipidaemia 4 
heart rhythm 
- s i n u s 75 
- atr ial f ib r i l la t ion 24 
- 2:1 block 1 
blood chemistry 
- potassium (mmol/1) 4.0*0.4 
- haematocrit (1/1) 0.43+0.05 
TABLE II 
DIAGNOSIS AND LOCALISATION OF STROKE IN 100 ADMITTED PATIENTS 
Area Cerebral infarction(n=88) TIA(n=12) 
left middle cerebral artery 38 
right middle cerebral artery 37 
left + right middle cerebral artery 2 
basilar artery 6 
posterior artery 3 
anterior artery 2 
TABLE III 
CHANGE IN MEDICATION (N=16) IN THE THREE WEEKS PRECFDING STROKE 
IN THE 100 PATIENTS STUDIED 
DRUG started dose increased stopped 
furosemide 
acetosal/dipyridamol 
acenocoumarol 
triamterene 
isosorbide dinitrate 
haloperidol 
penicillin 
reserpine-dihydralazine-
hydrochlorthiazide 
1 
1 
1* 
in these patients furosemide was started also 
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Table II lists the diagnoses and localisations of infarction and 
transient ischaemic attack. Cerebral infarction was diagnosed in 88 
patients, and transient ischaemic attack in 12. 
In 16 patients the treatment had been changed during the previous 
three weeks (Table III): 12 had started treatment with new drugs 
(furosemide as well as triamterene in one), two had had their dosages 
increased, and three had stopped taking drugs (one patient had 
stopped taking acenocoumarol and had started taking furosemide). 
The figure shows the changes in mean arterial blood pressure after 
infarction and transient ischaemic attack. 
Δ M A P C / . ) -
50-
40-
30 
20 
10-
ш ^ ™ ™ 
-10-
-20 
Fig. 1. 
Change (percentage) in mean arterial pressure (ΔΜΑΡ) in 100 patients 
admitted with stroke. 
Black bars represent five patients whose treatment was changed 
because of oedema (E) and hypertension (H); dotted bars represent two 
patients whose treatment was changed because of heart failure (F). 
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Mean arterial pressure increased in 71 patients and decreased in 29. 
The marked bars 1n Fig. 1 indicate the patients who started or 
increased their dosage of antihypertensive or diuretic treatment 
during the previous three weeks. 
Table IV shows the data on these seven patients. For illustration one 
case history (case 6) is presented. 
Case history 
A 72 year old woman had no history of pre-existing hypertension, 
congestive heart failure or diabetes mellitus and was not receiving 
any treatment but sometimes complained of dizziness. The general 
practitioner had been called to her home because she was confused and 
had loss of vision in the right eye and loss of strength in one hand. 
On his arrival the neurological signs had disappeared, but because of 
her blood pressure of 190/115 mmHg furosemide (40 mg daily) was 
started. After two days she complained of a constant dizziness and 
was dysphasic; on admission she had right sided hemianopsia and 
paralysis of the right arm and leg. Pulsations of the carotid 
arteries were normal without bruits, an electrocardiogram showed a 
sinus rhythm, and haematocrit was 0.48. A cerebral computerised 
tomography scan showed infarction in the left occipital area. On 
admission her blood pressure was 160/90 mmHg; the decrease In mean 
arterial pressure was 19%. 
DISCUSSION 
Cerebral ischaemia occurring as a side effect of treatment for hyper-
tension has been reported previouslyl5-23# in our study seven of 
100 patients had important changes in antihypertensive or diuretic 
treatment during the three weeks before their stroke. We believe that 
these changes caused a decrease in blood pressure and an Increase in 
the haematocrit value that contributed to the stroke in four 
patients. We realize that the blood pressures used in the study are 
based on few measurements and that the blood pressures before the 
stroke, all recorded by the general practitioner, had led to the 
decision to start treatment for hypertension or to increase the dose. 
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TABLE IV 
en 
SEVEN PATIENTS WITH START OR DOSE RISE OF ANTIHYPERTENSIVE/DIURETIC TREATMENT IN THE THREE WEEKS BEFORE STROKE 
(M = male, F = female, CHF = congestive heart failure, BP = blood pressure, HR = heart rate and rhythm, 
HT = haematocnt, SR = sinus rhythm, AF = atrial fibrillation, RMA = right middle cerebral artery, 
LMA = left middle cerebral artery, PA = posterior cerebral artery) 
Patient 
1 
2 
3 
h 
5 
6 
7 
Age(yr) 
sex 
Θ1 
M 
75 
M 
69 
M 
79 
F 
67 
F 
72 
F 
72 
M 
medication 
digoxin 
insulin 
(acenocoumarol 
1 week stopped) 
sulphonyl urea 
salbutamol 
Furosemide 
(40 mg twice 
weekly) 
new drug 
or dose rise 
(period) 
furosemide 
(10 days) 
(80 mg) 
furosemide 
(1 day 40 mg) 
Furosemide 
(10 days 
40 mg once 
daily) 
reserpine-dihydralazine-
hydrochlorthiazide 
(1x1) (6 days 2x1) 
metoprolol 
digoxin 
-
methyldopa 
glybencl amide 
furosemide 
(17 days 
40 mg on 
alternate days 
furosemide 
(2 days 40 mg) 
furosemide 
40 mg and 
triamterene 
(7 days 1x1) 
indication 
CHF 
CHF 
oedema 
hypertension 
hypertension 
) 
hypertension 
hypertension 
BP before 
treatment 
(mmHg) 
150/80 
210/110 
120/90 
220/130 
170/115 
190/115 
160/110 
BP»after 
stroke 
(mmHg) 
155/100 
220/115 
130/70 
193/115 
150/90 
160/90 
140/78 
ΔΜΑΡ 
(Я) 
+15 
+ 5 
-10 
-12 
-18 
-19 
-22 
HR 
104 SR 
112 SR 
150 AF 
88 SR 
76 AF 
68 SR 
92 SR 
HT 
(1/1) 
0.41 
0.38 
0.33 
0.48 
0.51 
0.48 
0.52 
diagnosis 
infarction 
LMA 
infarction 
RMA 
infarction 
LMA 
infarction 
LMA 
infarction 
RMA 
infarction 
PA 
infarction 
LMA 
* mean of two values 
Side effects of such treatment are better studied prospectively, but 
we consider it unethical to start incorrect treatment to determine 
severe side effects. We therefore felt obliged to confine ourselves 
to this retrospective study despite its shortcomings. 
The relationship between change in treatment and stroke is difficult 
to prove in this study because risk factors for stroke were present 
in all the patients: five had hypertension, two had atrial fibrilla­
tion, one had had a transient ischaemic attack two days before com­
plete stroke, two had diabetes mellitus and one (case 2) had stopped 
taking acenocoumarol one week before the event. Nevertheless, we 
believe that in cases 4, 5, 6 and 7 the change in treatment has at 
least contributed to the pathogenesis of the stroke. In cases 1, 2 
and 3 the relation between treatment and stroke is less likely 
because of the lack of signs of haemoconcentration, the increase in 
blood pressure (cases 1 and 2), the cessation of treatment with 
acenocoumarol in case 2 and the uncontrolled atrial fibrillation in 
case 3. 
In our opinion the elderly are especially at risk of cerebral 
ischaemia from reduced blood pressure for several reasons. Firstly, 
the baroflex is less sensitive in old people and a quick decrease in 
blood pressure cannot be compensated immediately as in the young26. 
Secondly, cerebral autoregul at ion may be impaired in the elderly27
> 
The brain is protected from fluctuations in blood pressure by auto-
regulation. When blood pressure decreases the cerebral vessels 
dilate; when blood pressure increases they constrict, resulting in a 
constant cerebral blood flow at mean arterial pressures ranging from 
60 to 150 mmHg in normal subjects. The brain of patients with chronic 
hypertension is more vulnerable to hypotension because the cerebral 
autoregulatory curve shifts to the right; in these patients a 
reduction of cerebral blood flow occurs at a higher arterial oressure 
than in normotensive subjects^, д reduction in mean arterial 
pressure of about 25% is required to reach the lower limit of 
cerebral blood flow autoregulation; a further reduction to about 5551! 
is needed to cause symptoms of brain hypoperfusion in both hyperten­
sive and normotensive subjects aged under 66 years29. 
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In 1956 an inverse correlation was shown between cerebral blood flow 
and age, with a pressure reduction of about 25% in the elderly 
compared with the young^O. This finding was later confirmed by 
other authors using more modern methods31t32# 
Thirdly, cerebral blood flow has a lower pressure with a high 
haematocrit value (over 0.46)33f though regulatory mechanisms can 
maintain normal cerebral oxygen transport despite increased viscosity 
of plasma and whole blood34. 
Atherosclerosis might be considered important in decreasing the 
flexibility of arteries in the brain, patients with the most pronoun-
ced arteriosclerosis being most at risk of stroke in the event of a 
hypotensive episode. Several studies, however, do not support this 
concept^,36. Torvik and Skullerud studied 115 cases of cardiac 
arrest and found no correlation between the degree of arteriosclero-
sis and the risk of brain infarcts as a complication of the hypoten-
sive ep1sode36. There is a relation between the morphological 
substrate and the outcome of a period of hypotension as shown by the 
neuropathological observations of 11 patients by Adams et al.37; 
the necrosis of grey and white matter at the boundary zones 
("watersheds") seemed to be attributable to a precipitate reduction 
in systemic blood pressure, while diffuse alterations seemed to be 
the result of a moderate but sustained systemic hyootension. 
For these reasons and because the elderly are more likely to suffer 
side effects38-39> blood pressure should be reduced gradually and 
treatment started with a small dose of relatively safe antihyperten-
sive agent. Primarv, treatment for hypertension in the elderly is 
generally with a thiazide diuretic39. 
Inappropriate antihypertensive treatment may cause stroke: powerful 
high ceiling diuretics such as furosemide may induce hvpovolaemia and 
hypotension, resulting in cerebral ischaemia.In the treatment of 
hypertension these drugs are best avoided. 
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CHAPTER б 
CEREBRAL INFARCTION AS CONSEQUENCE OF INAPPROPRIATE 
ANTIHYPERTENSIVE TREATMENT 
PAF Jansen, BPM Schulte, EFJ Poels, RHB Meyboom, FWJ Gribnau 
Submitted for publication 
SUMMARY 
Cerebral ischaemia as possible side effect of medication was studied 
in 54 patients treated with antihypertensive drugs and admitted to 
hospital because of a cerebral infarction. Three patients (ages 67, 
72 and 72) had started furosemide within the three weeks before 
stroke because of hypertension; all three patients had a marked fall 
in blood pressure after stroke as compared with pretreatment levels. 
The case histories of the 3 patients are presented. It is concluded 
that the powerful heigh-ceiling diuretic furosemide may cause hypo-
volaemia and hypotension and may so contribute to the occurrence of 
stroke, especially in elderly patients not suffering from congestive 
heart failure. 
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INTRODUCTION 
Hypertension is the most important risk factor for cerebrovascular 
diseasesl»2. Effective antihypertensive treatment reduces morbidity 
and mortality of these disorders^, in elderly hypertensive pa-
tients^"? as well. It is therefore to be expected that more and 
more aged patients will be treated with antihypertensive drugs. 
In drug treatment, adverse reactions are not uncommon. Of the several 
antihypertensive agents now in use, many unwanted effects are known; 
some are dose-independent but most are dose-dependent. Detection of 
an adverse drug reaction is extremely difficult when the clinical 
manifestation is identical with the disease that the drug tried to 
prevent. We studied cerebral ischaemia as possible side effect of 
antihypertensive treatment. The aim was to establish whether oral 
antihypertensive or diuretic treatment, inducing a steep fall in 
blood pressure, may cause cerebral infarction. 
MATERIAL AND METHODS 
Over a period of one year all patients admitted to a general hospital 
with cerebral infarction and using antihypertensive or diuretic 
agents, were studied. The general practitioners of the patients were 
asked by telephone for the indication to prescribe such drug treat­
ment; blood pressure values were also asked for. Only the blood pres­
sures measured a few days to one year before the cerebral infarction 
were considered of value. A series of 54 patients was thus formed. In 
the emergency department blood pressure was measured and blood was 
sampled for measurement of sodium, potassium, creatinine, blood urea 
nitrogen, haemoglobin, haematocrit and albumin. In the neurological 
department blood pressure was measured at least every six hours by 
trained nurses. The values are expressed as mean arterial pressure 
(MAP): MAP = diastolic + 1/3 pulse pressure (mmHq). 
The change in blood pressure after the event is expressed as ΔΜΑΡ: 
дмдр = MAP after the event - MAP before the event
 x
 100% 
MAP before the event 
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As "MAP after the event" the mean of the first two blood pressure 
measurements was taken (the one in the emergency department and the 
first one in the neurological department respectively). On the first 
day after admission a cerebral CT-scan was performed. Cerebral in­
farction was diagnosed by a neurologist according to the criteria of 
the WHO8. 
RESULTS 
Clinical details on the 54 patients studied are listed in Table I. 
The antihypertensive and diuretic drugs used by the patients, are 
listed in Table II. None of the 16 patients with diabetes mellitus, 
showed a severe dysregulation of the blood sugar and none of the 54 
patients had diarrhoea as a cause of hypovolaemia. Five patients had 
started an antihypertensive or diuretic drug within 3 weeks before 
the event. In all five cases the drug involved was furosemide, in two 
cases given because of congestive heart failure and in the other 
three because of hypertension. The ΔΜΑΡ of the patients is presented 
in Fig. 1. Thirty-seven patients (69%) had an increase in MAP after 
cerebral infarction and seventeen (31%) a fall. The two patients 
given furosemide because of congestive heart failure had an increase 
of 5 and 15% respectively. The three patients given furosemide 
because of hypertension, however, had a decrease in MAP by 18, 19 and 
22% after cerebral infarction. These three patients had the most 
marked fall in blood pressure of all patients (they are marked with 
the black bars in Fig. 1). The case histories of these patients are 
presented. 
CASE HISTORIES 
Patient A, a woman aged 67 years, had had hypertension, atrial fi­
brillation and non-dependent diabetes mellitus for some years. She 
used metoprolol once daily and digoxin 0.125 mg daily as medication. 
Check of the blood pressure revealed that it was still increased 
(170/115 mmHg) and she had been prescribed furosemide 40 mg on alter­
nate days. After seventeen days treatment the patient had noted loss 
of strength in the left arm and leg and there had been falls. At ad-
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TABLE I. Clinical details on the 54 patients in this study 
(in part mean ± S.D.) 
Sex and age 
women 
men 
age (years) 
39 
15 
73±9 
Laboratory 
sodium (mnral/1) 
potassium (mmol/1) 
creatinine (μπιοΐ/ΐ) 
blood urea (mmol/1) 
haemoglobin (mmol/) 
haematocrit (1/1) 
albumin (g/1) 
140±4 
3.9±0.4 
104±39 
7.6+2.7 
9.3±1.1 
0.44±0.05 
38±4 
TABLE II. Antihypertensive and diuretic drugs used by the 54 patients 
(n = number of patients) 
Agents 
thiazide diuretic 
furosemide 
ß-blocking drug 
methyl dopa 
triamterene 
Captopril 
labetalol 
prazosine 
Adelphan-Es1drexR 
r^  
25 
19 
18 
7 
5 
2 
2 
1 
1 
indication η 
hypertension 36 
congestive heart failure 18 
number of agents used 
simultaneously 
1 agent 31 
2 agents 20 
3 agents 2 
4 agents 1 
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mission a left-sided hypotonie hemiparesis was present. Blood pres­
sure was 150/90 mmHg (ΔΜΑΡ -18%). The heart rate was 76 beats per 
minute, and irregular. There were normal carotid artery pulsations 
without bruits. The ECG showed atrial fibrillation with a ventricular 
rate of 76 beats per minute. A cerebral CT-scan showed a right-sided 
infarction in the parietotemporal area. Blood chemistry: sodium 
140 mmol/l, potassium 3.0 mmol/1, blood sugar 14.7 ranol/l, creatinine 
71 μπιοΐ/ΐ, blood urea 5.0 mmol/1, haemoglobin 10.8 mmol/1, haemato-
crit 0.51 1/1 and albumin 42 g/1. The patient had been given an 
isotonic salt infusion, with an increase in blood pressure to 
170/110 rmiHg as a result. Because of development of congestive heart 
failure after a few days, it was decided to continue the furosemide. 
The hemiparesis recovered partly. 
Patient B, a woman aged 72 years, had always been in good health. She 
sometimes suffered from dizziness. The general practitioner was 
called to her home because of confusion and loss of strength in the 
right hand; at the time of his visit, all neurological disturbances 
had disappeared. The patient's blood pressure was 190/115 mmHg and 
therefore furosemide 40 mg once daily was prescribed. After two days 
the patient compiainted of constant dizziness, she was dysphasic and 
there was again loss of strength in the right hand. At admission dys­
arthria, right-sided hemianopsia and right-sided paralysis of the arm 
and leg were present. Blood pressure was 160/90 (лМАР -19%). There 
were normal carotid artery pulsations. The ECG showed sinus rhythm. 
The cerebral CT-scan revealed an infarction in the left occipital 
area. Blood chemistry: sodium 141 mmol/1, potassium 3.7 mmol/l, 
creatinine 80 μπιοΐ/1, blood urea 5.7 mmol/1, haemoglobin 10.0 mmol/1, 
haematocrit 0.48 1/1 and albumin 45 g/1. The furosemide treatment was 
not stopped. Blood pressure ranged between 140/80 and 170/90 mmHg in 
the next few days. The hemiparesis disappeared. 
Patient C, a man aged 72 years, had had hypertension and diabetes 
mellitus for some years. He used methyldopa twice daily, qlibencla-
mide thrice daily and a diet free of salt and sugar. The blood 
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Fig. 1. 
Chanqe of blood pressure in the 54 patients on the first day after 
cerebral infarction as compared with the level measured a few days to 
one year before the event, expressed as ΛΜΑΡ {%). The marked bars 
represent the 3 patients described. 
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blood pressure was found to be 160/110 mmHg. Furosemide 40 mg once 
daily and triamterene once daily were added to the therapy. After 
seven days be became drowsy, complainted of dizziness, had distur­
bance of speech and loss of strength in the right arm and leg. At 
admission a right-sided hemiparesis was present. The patient was 
drowsy and dysphasic. Blood pressure was 140/78 mmHg (ΔΜΑΡ -22%). 
There were normal carotid artery pulsations, without bruits. The ECG 
showed sinus rhythm. The cerebral CT-scan showed no abnormalities. 
EEG showed abnormal function of the brain in the left fronto-temporal 
area. Blood chemistry: sodium 142 mmol/1, potassium 3.5 mmol/1, 
creatinine 100 μίποΐ/ΐ, blood urea 7.2 ranol/l, blood sugar 15.5 mmol/ 
1, haemoglobin 11.1 mmol/1, haematrocrit 0.52 1/1 and albumin 43 g/1. 
At admission methyl dopa and triamterene were stopped and the patient 
was given extra fluid via a catheter. Blood pressure increased to 
170/90 rmiHg. Furosemide was not stopped. The hemiparesis partly dis­
appeared. 
DISCUSSION 
In our opinion antihypertensive treatment with furosemide at least 
contributed to the occurrence of stroke in these 3 patients. They all 
had a marked fall 1n blood pressure after cerebral infarction in com­
parison with pre-treatment levels. A fall in blood pressure after 
stroke is remarkable because in most patients it is Increased on the 
first day after the event; a Dutch epidemiological study revealed an 
increase in blood pressure in 90% of the patients with stroke'. 
In our view 1t is therefore not a coincidence that the 3 patients 
described are on the left side of Fig. 1. The powerful high-ceiling 
diuretic furosemide may cause a steep fall in blood pressure; in the 
3 patients a high haematocrit value and relatively high plasma 
albumin concentration were present reflecting hypovolaemla. The cli­
nical evidence in such cases is not complete; in the patients other 
risk factors for stroke were present, like the hypertension itself, 
diabetes mellitus and (in one) atrial fibrillation. In the two 
patients with diabetes mellitus the blood sugar was not grossly dys-
regulated; in the patient with atrial fibrillation, the ventricular 
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rate was not high. One patient suffered a TIA two days before the 
event; in this case failure of cerebral autoregulation was possibly 
present, as described in patients with stroke^; the cerebral blood 
flow is directly dependent on blood pressure in such a situation, 
resulting in cerebral ischaemia even after only a rather small fall 
in blood pressure. Because it was not clear at admission why furose-
mide was prescribed in the 3 patients, it was not stopped in the 
first days after stroke. Blood pressure values as measured before 
stroke, are usually not known at the time of the event; even a marked 
fall in blood pressure after the event may therefore easily remain 
unnoticed and stroke as side effect of antihypertensive treatment not 
considered. In literature thirty such patients have been report-
edll. The pathology of cerebral ischaemia induced by hypotension, 
was studied by Adams et al.12. After a quick fall in blood pres-
sure, they found lesions in the "watershed areas", the border zones 
of the main cerebral arteries; more diffuse alterations were seen 
after a moderate but prolonged lowering of the pressure. 
For several reasons the elderly are especially at risk for developing 
cerebral ischaemia after a quick or steep fall in blood pressure. 
Firstly, the baroreceptor is less sensitive in the aged, and lowering 
of blood pressure cannot be compensated as adequately as in the 
youngl3. Another point of importance is the shift to the right of 
the autoregulatory curve of the brain in patients with longstanding 
hypertensionl4,15t jh-js autoregul at Ion guarantees a constant cere-
bral blood flow in MAP ranges from 60 to 150 imiHg; when blood pres-
sure increases, vessels constrict and prohibit increase of blood flow 
and vice versa. In patients with hypertension, there is failure of 
cerebral autoregul at i on, with reduction of cerebral blood flow at 
higher MAP levels than in normotensives. 
In the elderly (over 65 years of age), cerebral autoregulation can be 
impaired even in the absence of hypertension^. 
Moreover, cerebral blood flow decreases with increasing age^7»^. 
Finally, cerebral blood flow is lower with a high haematocrit (over 
0.46). The elderly patient with hypertension and a high haematocrit 
is therefore especially at risk for cerebral Ischaemia after a quick 
81 
or steep reduction of blood pressure. The drug of choice in the 
treatment of hypertension in the aged is usually a thiazide diure-
tic20,21# jhe high-ceiling diuretics, like furosemide, are quick 
and powerful and may cause a steep fall in blood pressure^; they 
are therefore inappropriate for the treatment of hypertension. In the 
case of congestive heart failure there is a good indication to pre-
scribe high-ceiling diuretics; induction of diuresis causes no 
depletion of volume in such a situation, because fluid is replaced 
from the extravascular compartment23. Blood pressure should be 
monitored however, because hypovolaemia as a side effect of furose-
mide is frequently seen (4-14.5%), especially in the elderly 
patient24»25. 
In conclusion, when starting antihypertensive treatment, especially 
in an elderly patient, one should prescribe appropriate drugs aiming 
at a gradual lowering of the blood pressure. Because the high-ceiling 
diuretics are powerful, with a risk of hypovolaemia, hyootension and 
- as is suggested also by our results - even cerebral ischaemia, they 
are not suitable in the treatment of hypertension. 
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CHAPTER 7 
COURSE OF BLOOD PRESSURE AFTER CEREBRAL 
INFARCTION AND TRANSIENT ISCHAEMIC ATTACK 
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cerebrovascular disease, september 1986. 
ABSTRACT 
In 63 patients, admitted for cerebral infarction or transient 
ischaemic attack (TIA), the blood pressure course was studied. The 
blood pressure before the event was studied retrospectively; 32 
patients were normotensive, in 31 patients existed hypertension, with 
antihypertensive treatment in 15 of these cases. The blood pressure 
after the event was studied prospectively, and turned out to be risen 
in 67% of the patients on the day of admission. It fell in the first 
days after infarction or TIA, mainly on the second day, to a plateau 
level reached on the fifth day. Only 3 patients (5%) remained hyper-
tensive until discharge from the hospital. In 48 patients blood 
pressure values were available as measured two to six months after 
discharge, without a change in antihypertensive medication. Blood 
pressure appeared increased compared to the value measured before 
discharge. In 14 patients {29%) hypertensive blood pressure figures 
were measured at that time. It is concluded that blood pressure is 
elevated in the acute phase of cerebral infarction and TIA, but falls 
spontaneously in the first days to normotensive levels in most 
patients; because blood pressure may increase again, measurements of 
blood pressure within the first months after discharge are needed. 
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INTRODUCTION 
The onset of stroke is usually accompanied with elevation of blood 
pressure. Most authors advise not to treat elevated blood pressure in 
the acute phase of ischaemic stroke, except in patients with hyper-
tensive encephalopathy^'^. The reason not to treat post-stroke 
hypertension is that autoregul at i on may be impaired in the first 
weeks after stroke, relating cerebral blood flow directly to systemic 
blood pressure^; even a minor fall in blood pressure may cause a 
decrease in blood flow in the ischaemic area, aggravating cerebral 
ischaemia and enlarging the infarct. However, there is no general 
agreement about the management of hypertension in the acute phase of 
stroke5-6. 
There are only a few reports in literature about the changes in blood 
pressure after stroke^'lO. It is shown that after an early blood 
pressure elevation, tension falls spontaneously mainly in the first 
three days after the event, in all types of strokes. Blood oressure 
falls to or below premorbid levels. 
We studied the changes in blood pressure measured before, in the 
first days after and a few months after cerebral infarction and 
transient ischaemic attack (TIA). 
MATERIAL AND METHODS 
^tud/ design; patients 
The blood pressure course was studied in 63 patients, admitted to a 
general hospital because of acute cerebral infarction (n=53) or TIA 
(n=10). Twenty one patients with cerebral infarction and three with 
TIA used antihypertensive treatment. This treatment remained unchang-
ed during their stay in hospital. In none of the patients antihyper-
tensive or diuretic drugs were started. The population studied 
comprised 38 women and 25 men aged 74+8 years (mean +SD), range 51 to 
89 years. Cerebral infarction or TIA was diagnosed according to the 
criteria of the WHO^. At admission the blood pressure was recorded 
with a sphygmomanometer in the emergency department, during the first 
three days at least every six hours in the neurology department, and 
every 12 hours from then on. This was done by trained nurses. The 
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blood pressure values before infarction or TIA were measured two 
weeks to one year before stroke by the general practitioner. 
The blood pressure values after discharge from the hospital were 
measured two or six months after infarction or TIA by the general 
practitioner or nursing home physician, all before an eventual 
change in antihypertensive or diuretic medication. Blood pressures 
are expressed as mean systolic or diastolic pressures (±SD) or as 
mean arterial pressure (MAP): 
MAP = diastolic blood pressure + 1/3 (systolic-diastolic blood 
pressure). 
For statistical analysis paired and independent sample t-tests were 
used, respectively, for comparison of the MAP values of the first 
days after the event and for comparison of the MAP values of three 
patient groups (with pre-existing hypertension, with and without 
antihypertensive therapy, and with no pre-existing hypertension). 
RESULTS 
The spontaneous changes in blood pressure in the 63 patients are 
presented in Fig. 1. Before infarction or TIA mean blood pressure was 
159/92 + 25/10 rmiHg, with a MAP of 115+14 mmHg. Forty patients (63%) 
were known to the general practitioner as hypertensive according to 
the criteria of the WHOl2 (i.e. systolic >160 and /or diastolic 
>95 mmHg) before the event. Of these 40 patients, 16 received no 
antihypertensive therapy; of the 24 patients under treatment, 15 
responded insufficiently to antihypertensive therapy. 
At admission to the emergency department the highest blood pressure 
levels during stay in hospital were measured: 183/104±31/15 mmHg, MAP 
130±19 mmHg. The first measured blood pressure in the neurology 
department was both systolic and diastolic considerably lower 
(168/95±29/14 mmHg, MAP 120±18 mmHg). On the first day after infarc-
tion or TIA, 67% had elevated blood pressure. The blood pressure fell 
spontaneously the following days, to a level of 141/81tl8/8 mmHg, MAP 
101±10 mmHg. Because blood pressure sometimes fluctuated markedly, 
the maximal, minimal and MAP measurements are also depicted in Fig. 
1. The blood pressures measured on the first day (1) include the 
90 
first blood pressure measured in the neurology department (Ν), but 
not the blood pressure measured in the emergency department (E). The 
greatest difference in MAP existed between the first and second day 
after stroke. The fall was significant (p<0.001). The MAP on the 
fifth day and before discharge were nearly identical (lOltlO mnHg and 
Blood pressure (mm Hg) 
Course of systolic and diastolic blood pressure and MAP (-) values 
(mean ± SO) of the 63 patients in this study; blood pressures were 
measured 2 weeks to one year before the event at home (H), in the 
emergency department (E), on the first to fifth day (1-5) and before 
discharge (D). N represents the first measurement in the neurology 
department. The maximal and minimal systolic and diastolic blood 
pressures of the first to fifth day are shown. The blood pressure 
measured in E is not included in the blood pressure figures of the 
first day. 
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lOOill mmHg, respectively) and were considerably lower (p<0.001) than 
the premorbid levels (MAP 115+14 mmHg). 
At discharge only 3 patients (5%) were still (slightly) hyper­
tensive. 
Apart from the blood pressure values measured at home, the MAP of the 
patients with TIA were at any time lower (although not significantly) 
than the MAP of the patients with an infarction (Fig. 2). 
M.A.P. ( m m Hg) 
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Fig. 2. 
Course of MAP (±SD) of the patients with cerebral infarction or TIA 
in this study. For explanation of the letters on the abscissa see 
Fig. 1. 
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Fig. 3 shows the blood pressure course of patients with pre-existing 
hypertension with antihypertensive treatment (n=24), with pre­
existing hypertension without antihypertensive treatment (n=16) and 
without pre-existing hypertension (n=23). In the first days after the 
event there was a striking parallel between the three curves. The MAP 
of the patients without ore-existing hypertension was at any ooint 
lower than the MAP of the hypertensive patients. Before the event, on 
the 4th and 5th day after it and before discharge this difference was 
significant (p<0.05). 
M.A.P. (mmHg) 
I I I I I Ι ι ι ι 
H E N 1 2 3 4 5 0 
Fiq.3. 
Course of MAP of the patient groups with pre-existent hyper-tension, 
with and without antihypertensive therapy, and without pre-existent 
hypertension. For explanation of the let ters on the abscissa see 
Fig. 1. 
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The patients were discharged to home (n=51) or nursing home (n=12). 
Of 48 patients with infarction (n=40) or TIA (n=8) blood pressure 
data were available, measured two to six months after discharge from 
hospital; these patients had not changed their antihypertensive/ 
diuretic medication. The other patients had died, were lost to 
follow-up, or their data could not be used because of change in anti-
hypertensive/diuretic medication. The course of the MAP of the 48 
patients, measured before, in the first days after and two to six 
months after discharge is shown in Fig. 4. 
M.A.R (mmHg) 
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Fig. 4. 
Course of MAP (±S0) of 48 patients with infarction (n=40) or TIA 
(n=8) measured before, directly after and two to six months after 
discharge from hospital (A). 
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The MAP measured after discharge (A) was higher (p<0.01) than that 
before discharge (D), but still lower (p<0.01) than the MAP measured 
before the event at home (H). Of the 48 patients, 35 were known to 
the general practitioner with pre-existing hypertension. Twenty-three 
patients were on antihypertensive drugs; 26 patients had hypertensive 
blood pressure values (14 patients with treatment, 12 without). After 
the event and until discharge only three patients remained hyperten-
sive (two received antihypertensive medication). Blood pressure 
measurements two to six months after discharge revealed hypertensive 
M.A.P. (mmHg) 
Fig. 5. 
Course of MAP in the three patient groups with pre-existent hyper-
tension, with and without theraoy, and without pre-existent hyper-
tension. 
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blood pressures in 14 patients (from these, 9 patients were on anti­
hypertensive therapy). All patients with normotension before the 
event remained normotensive up to 2 to б months after the infarction 
or TIA. After discharge MAP returned to the premorbid level in the 
normotensive patients (Fig. 5). In the patients with pre-existent 
hypertension and antihypertensive therapy the MAP level also rose 
after discharge, but remained slightly lower than the level before 
the event; the difference (113+15 mmHg vs 118+12 mmHg) was not signi­
ficant. The MAP level of the patients with pre-existent hypertension 
without antihypertensive medication, increased after discharge to a 
mean of 110 (±15) mmHg; compared to the pre-morbid MAP level (127±9) 
their blood pressure was still significantly lower (p<0.01). 
DISCUSSION 
The change in blood pressure after stroke without specific antihyper­
tensive therapy was studied in 334 patients by Wallace and Levy8. 
For all types of stroke they found high blood pressure values 
(systolic as well as diastolic) at admission; a spontaneous decrease 
in blood pressure to normotensive levels was seen within the first 
ten days after admission in all categories of stroke. The patients 
with intracerebral haemorrhage had highly variable blood pressures; 
in this patient group the systolic blood pressure decreased, but the 
diastolic blood pressure did not change in the first days after 
stroke. 
We studied 63 patients with cerebral infarction (n=53) or TIA (n=10) 
as to the spontaneous blood pressure course before, anddirectly after 
the event and two to six months after discharge from hospital. Our 
results are comparable with those reported by Wallace; in most 
patients we found hypertensive blood pressure levels after infarction 
or TIA; within a few days blood pressure fell to normotensive levels 
without change 1n antihypertensive medication. The highest blood 
pressure values were recorded in the emergency department. This may 
be due to the stress of the event. In view of the difference in blood 
pressure between the emergency department and the neurology depart-
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ment it is of importance to transfer patients with stroke to the 
neurology department as soon as possible, and moreover it seems 
advisable to decide on antihypertensive intervention, if any or ever, 
only on the basis of values obtained in the neurological ward. 
The most marked fall in blood pressure occurred from the first to the 
second day after the event; the difference was statistically signifi-
cant. On the second to fifth day a further gradual fall in blood 
pressure was seen to plateau values in the order of the blood 
pressure value measured before discharge from the hospital. This 
level was significantly lower than premorbid levels. 
Clearly the patients with TIA were admitted because of long duration 
of the event. After the TIA they had lower blood oressures than the 
infarction group; one might therefore conclude that the severity of 
cerebral ischaemia apparently determines the degree of increase in 
blood pressure after the event, possibly as a natural defense mecha-
nism for the benefit of blood flow in the ischaemic area. 
After discharge blood pressure rose again, but remained below pre-
morbid levels. Especially the patients with previous hypertension and 
no antihypertensive therapy had MAP levels (measured two to six 
months after the event) far below premorbid levels. We have no 
complete explanation for this finding, but it may at least partly 
result from changes made by the patients in their way of life. 
However, this group was small. It should be emphasized that blood 
pressure measurements are necessary in the first months after dis-
charge, because hypertension can return and antihypertensive treat-
ment can prevent stroke recurrence^, 14j although not in the 
elderlyl5.!6. 
Since antihypertensive treatment in the acute phase of stroke might 
be dangerous!?, and the blood pressure falls spontaneously after 
stroke, mainly between the first and second day, as shown by our 
results and other studies?"^, no additional antihypertensive 
treatment should be instituted in the first days after stroke unless 
signs of hyoertensive encephalopathy are present. Frequently, anti-
hypertensive medication can even be stopped during the stay in 
hospital because the blood pressure normalizes spontaneously; 
97 
however, blood pressure measurement after discharge is needed because 
patients with a normalized post-stroke blood pressure during their 
stay in hospital may become hypertensive again after a few months. 
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CHAPTER 8 
BLOOD PRESSURE AND BOTH VENOUS AND URINARY 
CATECHOLAMINES AFTER CEREBRAL INFARCTION 
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ABSTRACT 
Blood pressure, both venous and urinary catecholamines and plasma 
renin activity (PRA) were studied in 10 patients (6 men and 4 women, 
mean aqe 70 ± 10 years) on the first three days after cerebral 
infarction. Blood pressure fell significantly (p<0.02) on the second 
and third day after stroke. There was a small but significant 
(p<0.01) decrease in plasma epinephrine concentration on the third 
day. The norepinephrine values remained constant on the three days. 
The PRA showed a significant (p<0.01) rise on the third day. No sig-
nificant correlation was detected between the course of the blood 
pressure and the plasma catecholamines or PRA. When blood pressure 
was correlated with the urinary catecholamines, however, a signifi-
cant correlation with epinephrine (r=0.44; p<0.05) and dopamine 
(r=0.44; p<0.05) but not with norepinephrine (r=0.06; p>0.05) was 
found. We conclude that the changes in blood pressure after stroke 
are at least partly mediated by the changes in catecholamine produc-
tion. 
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INTRODUCTION 
In the acute phase of stroke blood pressure is often increased5,12, 
18,21. During the first days after the event blood pressure 
decreases spontaneously, mainly between the first and the second day, 
to a mean baseline level, that is reached on the average on the fifth 
day. Post-stroke hypertension is present in all types of stroke. 
However, in the case of cerebral haemorrhage the highest blood 
pressure levels were found, whereas after cerebral infarction the 
blood pressure increase was smaller21; in both cases the fall in 
blood pressure after the event showed a similar pattern. 
The cause of post-stroke hypertension is not clear; the stress of the 
event and neuronal (dys)regulation of blood pressure have been 
suggested3.13# in ^ e first days after cerebral haemorrhage plasma 
epinephrine (E) and norepinephrine (NE) concentrations were found 
extremely high^·»^; on the first day after cerebral infarction and, 
to lesser extent, after transient ischaemic attacks, increased values 
of E, NE and dopamine concentrations have also been reported^. 
We studied the relationship between blood pressure levels and plasma 
concentrations of E, NE and renin activity (PRA) on the first three 
days after cerebral infarction. We also considered the relationship 
between blood pressure and the urinary excretion of E, NE and 
dopamine. 
METHODS 
Ten patients (6 male, 4 female) with cerebral infarction according to 
the criteria of the WHO^O were selected. The mean age (+SD) was 
70+10 years. All patients gave their informed consent. 
Four patients used anticoagulants, 2 diuretics and 1 a broncho-
dilator. The other 3 patients used no medication. During the study 
period medication had not been changed. On the first, second and 
third day after admission at 09.00 a.m. an intravenous catheter was 
placed in an antecubital vein, while the patient was kept in a 
recumbent position for at least 30 minutes. Then blood was collected 
for E and NE into an ice-cold tube containing 0.1 ml blood additive 
(0.25 mol/1 EGTA, 0.20 mol/1 GSH, in distilled water and brought to 
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pH 7.4 with 5 mol/l NaOH) and for PRA (EDTA tube). The tubes were 
capped, gently mixed and centrifuged at 40C as soon as possible. E 
and NE were measured as described by Hoffmann et al.H, PRA with a 
RIA method4. The reference values (+SD, range) of E, NE and PRA for 
normal adults in our laboratory are 0.165+0.05 nmol/1 (0.06-0.30), 
1.13+0.42 nmol/1 (0.60-2.20) and <2.78 ng/l/s respectively. 
Directly after blood collection blood pressure was measured with a 
sphygmomanometer by the investigator (PJ). 
Blood pressure was also measured every six hours by trained nurses 
during the study period. Blood pressures are expressed as systolic, 
diastolic and mean arterial pressure (MAP). MAP is the sum of the 
diastolic and 1/3 of the pulse pressure. Twenty-four hour urine was 
collected for creatinine, sodium, E, NE and dopamine measurement. In 
6 patients complete collection of urine was not possible due to in-
continence. All urine values are therefore expressed per mmol crea-
tinine. 
Urinary concentrations of catecholamines were measured using a modi-
fied method of Westerink et al.22. The reference values of E, NE 
and dopamine per mmol creatinine are 0.5-4.2 nmol, 5-34 nmol and 
40-160 nmol respectively. 
For statistical comparison Wilcoxon signed rank test and Spearman's 
rank correlation were used. A p-value of less than 0.05 was accepted 
as level of significance. Results are expressed as mean +SE, unless 
stated otherwise. 
RESULTS 
The systolic, diastolic and MAP values of the 10 patients, measured 
during the first three days after cerebral infarction at the time of 
blood collection and the mean of the four nurse readings, are pre-
sented in Figure 1. There was a significant (p<0.02) fall in systolic 
as well as in diastolic blood pressure from 161/96+8/4 on the first 
day to 149/90+6/5 on the second day, and to 140/84+5/5 rmiHg on the 
third day. The blood pressures measured at the time of blood collec-
tion were never significantly different from the values measured 
throughout the day. 
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In Figure 2 the mean values of E, NE and PRA of the first three days 
after cerebral infarction are presented. The plasma concentration of 
E was the highest on the second day with 0.55±0.11 nmol/1. The 
concentration of E on the third day was 0.41±0.09 nmol/1, which was 
significantly different (p<0.01) from that on the second day. 
Blood pressure ( m m Hg) 
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Fig. 1. 
Systolic, diastolic and MAP values (mean ±SE) in 10 patients, measur-
ed the first three days after cerebral infarction, at the time of 
blood collection (hatched bars) and throughout the day (open bars). 
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The concentration of NE on the three days was nearly constant: 
2.68+0.35,2.76+0.35 and 2.69±0.34 nmol/1 respectively. There was an 
increase in PRA from 0.17+0.03 on the first day, to 0.22±0.04 on the 
second day, to 0.38±0.06 ng/l/s on the third day. The PRA was signi­
ficantly (p<0.01) increased on the third day; the concentration was 
more than doubled on that day as compared with the first day after 
cerebral infarction. No significant correlation was found between MAP 
measured at time of blood collection (30 measurements), and E 
(r=0.36), NE (r=0.06) and PRA (r=-0.31), respectively. The urinary 
concentrations, expressed per mmol creatinine, of sodium. E, NE and 
dopamine are summarized in Table I. Due to incontinence in 5 patients 
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Fig. 2. 
Flasma concentrations (mean +SE) of epinephrine (E), norepinephrine 
(NE) and renin activity (PRA) in the 10 patients studied 
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TABLE I 
URINARY CONCENTRATIONS (MEAN +SE) OF SODIUM AND CATECHOLAMINES, 
EXPRESSED PER MMOL CREATININE, IN THE 10 PATIENTS STUDIED 
day 1 (n=7) day 2 (n=8) day 3 (n=8) 
Sodium mmol/mmol 6.7 ± 1.2 7.8 ± 1.9 6.1 ± 0.9 
Epinephrine nmol/mmol 3.6 ± 0.8 4.3 ± 1.0 2.5 ± 0.6 
Norepinephrine nmol/mmol 3 2 + 5 2 9 + 4 2 6 + 4 
Dopamine nmol/mmol 140 t 26 101 + 17 107 ± 14 
the 24 hour urine collection was not obtained for one day and in 
1 patient for two days. When the mean daily MAP values were corre-
lated with the urinary catecholamine excretion (23 measurements), a 
modest but significant correlation was found for E (r=0.44; p<0.05) 
and dopamine (r=0.44; p<0.05), but not for NE (r=0.06). 
DISCUSSION 
The early increase and spontaneous decrease of blood pressure after 
stroke is still unexplained. The present study shows that the course 
of blood pressure after cerebral infarction is not significantly 
related to the venous plasma concentrations of E, NE or PRA. While 
blood pressure fell in all patients, a nearly constant level of NE 
was found during the three days after cerebral infarction. Most of 
the patients studied were elderly, and plasma levels of NE are known 
to increase with age^. Moreover, elderly subjects show a greater 
rise in plasma NE in response to an uniform stress^.l^ The high NE 
concentrations are therefore difficult to interpret. Meyers et 
al.15 reported increased plasma E, NE and dopamine concentrations 
after cerebral infarction; the difference from a control group could 
not be explained by age, blood pressure, heart rate, stress or 
severity of stroke; in their material they found stable mean values 
on the first three days after the event for both E and NE. In 
contrast, we found a decrease of E in both plasma and urine on the 
third day. 
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For the increase of PRA on the third day, present in all 10 patients, 
we have no explanation; since the urinary sodium excretion was not 
different on the three days after cerebral infarction, an altered 
salt intake or an effect of diuretics (in 2 patients only) cannot 
have influenced the results. Smithl^ suggested a relationship be-
tween hypertension after carotid endarterectomy and renin production 
by the brain. Ganten et al.^»8 reported that the brain renin-angio-
tensin system is isolated from the peripheral renin-angiotensin sys-
tem; brain renin appeared not to leak in the periphery. A parallel 
production of brain and peripherally produced renin is, however, sug-
gested^. In case of cerebral ischaemia the brain renin production 
is increased and, due to the parallelism, the peripheral renin pro-
duction may be increased too. Therefore, the rise in PRA we found on 
the third day may be a late consequence of the cerebral ischaemia. 
Elevation of catecholamine excretion after stroke is well known, but 
the explanation remains uncertain 6,16,20. jhe relation we found 
between MAP and urinary excretion of E and dopamine respectively, 
suggests that the early increase and spontaneous fall in blood pres-
sure after cerebral infarction is mediated at least in part by the 
altered production of E and dopamine. Like Meyers^, we found 
stable concentrations of NE and no relation with blood pressure. 
In conclusion we found that the decrease of blood pressure on the 
first days after cerebral infarction was related to urinary excretion 
of E and dopamine, but not to NE concentration. We also found a 
doubling of the PRA on the third day after cerebral infarction as 
compared with the first day, possibly as a late consequence of the 
cerebral ischaemia. 
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CHAPTER 9 
SUMMARY AND CONCLUSIONS 
ANTIHYPERTENSIVE TREATMENT AS A POSSIBLE 
CAUSE OF STROKE IN THE ELDERLY 
SUMMARY AND CONCLUSIONS 
The elderly often suffer from multiple pathology and therefore they 
consume many drugs, frequently at the same time. Due to polypharmacy, 
interactions of the drugs, and altered pharmacokinetics and pharmaco-
dynamics in the elderly, a twofold increase of adverse drug reactions 
(ADR) is seen in patients over 70 years of age as compared with the 
young. Knowledge of possible drug interactions and of geriatric phar-
macology is therefore of importance to prevent iatrogenic disease in 
the aged. 
All drugs exert side effects. Recognition of a clinical sign as un-
wanted drug effect is sometimes easy, but more frequently it 1s dif-
ficult to assess an ADR. When a drug is prescribed to prevent a dis-
ease, it is difficult to prove that the disease is a result of an un-
wanted effect of the prescribed drug. We studied the possibility of 
stroke as ADR to antihypertensive treatment. 
In Chapter 1 the incentive for this study is described. The aim is to 
answer the question whether stroke as ADR to antihypertensive treat-
ment really occurs; if so, which drugs are responsible for it; are 
the elderly especially at risk to develop this ADR, and what is its 
incidence in a hospitalized stroke population. 
Before side effects of drugs can be assessed and treated, they have 
to be thought of. When a clinical sign is suspected as ADR, it has to 
be assessed and the relation between the drug and the suspected ad-
verse reaction can be described as unlikely (or doubtful), possible, 
probable, or definite. This assessment is notoriously difficult. 
There has been a number of methods and algorithms published for 
assessing causality. However, when different methods are used for the 
same cases, they do not necessarily yield the same results. 
In Chapter 2 stroke as side effect of antihypertensive treatment is 
assessed using two important methods. Only on the basis of time rela-
tionship between start of the drug and the event, the ADR was asses-
sed as possible. Major features of the methods, like dechallenge and 
rechallenge, were of no value because stroke is often irreversible. 
Moreover, a good alternative possible cause of stroke 1s always 
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present because hypertension is known to be the most important risk 
factor for stroke. However, the patients with stroke we suspected of 
having an ADR due to their antihypertensive treatment, all showed a 
remarkable and unexpected fall in blood pressure after the event and 
they had signs of haemoconcentration (high haematocrit values), fac-
tors pointing at stroke as ADR; these factors could not be implicated 
in any part of the methods. It was concluded that the commonly used 
algorithms and methods are not suitable in assessing antihypertensive 
treatment as a cause of stroke. 
Chapter 3 reviews the literature on reported cases of drug-induced 
cerebral ischaemia. We detected forty-four such cases. The patients 
showed signs of cerebral ischaemia such as confusion, drowsiness, 
collapse and stroke, induced by all kinds of antihypertensive drugs 
such as diazoxide, nitroprusside, high-ceiling diuretics, methvldopa, 
vasodilators, beta-blocking drugs and angiotensin-converting enzyme 
inhibitors. Relating the fall in mean arterial blood pressure (MAP) 
induced by the drugs to the age of the patients, it was seen that the 
young showed a marked fall of MAP, while in the elderly a rather 
small fall of MAP may result in cerebral ischaemia. It was concluded 
that the aged are especially at risk to develop cerebral ischaemia as 
ADR to antihypertensive drugs. Suggested explanations could be the 
impairment of baroreceptor sensitivity, possible failure of cerebral 
autoregul ation of the brain, and reduction of cerebral blood flow in 
the elderly as compared with the voung. 
Chapter 4 discusses an inquiry by questionnaire. A questionnaire was 
sent to all medical directors of Dutch nursing homes (n=322), because 
it was assumed that many patients with stroke, induced by hypotensive 
drugs, might be found in the populations of nursing home patients. 
The response was 55%. 
Thirty patients with signs of cerebral ischaemia or stroke developing 
within two weeks of the start of antihypertensive or diuretic drugs 
were reported by 25 physicians. All kinds of such drugs were report-
ed, but furosemide and methyldopa were mentioned especially. Nine of 
the thirty patients were well documented with full data on blood 
pressure measured inmediately after the event and compared with pre-
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treatment levels. The case histories of these elderly patients are 
presented. It was concluded that antihypertensive treatment in the 
elderly should start with a small dose of an appropriate drug, the 
aim being to reduce blood pressure gradually. 
In Chapter 5 a study among patients admitted to a general hospital 
because of cerebral infarction or transient ischaemic attack (TIA) is 
presented. One-hundred and seventy-eight patients were studied. Data 
on blood pressure values measured by the general practitioner a few 
days to one year before the event, were available on 100 of these 
patients. Only these 100 patients were included in the study. Seven 
of the 100 patients had had a change in antihypertensive or diuretic 
treatment within 3 weeks before the event. They all suffered a 
stroke. Three had started furosemide because of hypertension, two 
because of congestive heart failure; one patient had had an increase 
in furosemide dosage because of oedema of one leg and one had had an 
increase in Adelphan-Esidrex" dosage because of persistent hyper-
tension. Seventy-one of the 100 patients had an increase of MAP and 
twenty-nine a fall after the event as compared with pre-morbid 
levels. The 3 patients who had started furosemide because of hyper-
tension showed the most marked fall of MAP (18, 19 and 22% respecti-
vely). The patient with an increased Adelphan-Esidrex^ dosage had 
a fall in MAP of 12%. These four patients showed signs of haemocon-
centration (high haematocrit values). It was believed that the medi-
cation change was a factor contributing to the stroke in these elder-
ly oatients. The other 3 patients had a smaller decrease (10%) or 
even increase (5 and 15%) in MAP, and no signs of haemoconcentration 
were present. Since other risk factors for stroke were also present 
in these patients (atrial fibrillation with high ventricular rate and 
cessation of acenocoumarol one week before the event), the relation 
between medication change (start of furosemide because of congestive 
heart failure and increased furosemide dosage because of oedema of 
one leg) and stroke was considered as less likely. It was concluded 
from this study that especially high-ceiling diuretics such as furos-
emide, if used in the treatment of hypertension, may induce hypovol-
aemia and hypotension resulting in cerebral ischaemia. 
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In Chapter 6 a study on one category of the 100 patients described in 
Chapter 5 is presented; this category comprised only patients with 
cerebral infarction and using antihypertensive or diuretic drugs; 
this gave a series of 54 patients. The case histories of the 3 
patients who had started furosemide because of hypertension are 
given. It is pointed out that drug-induced cerebral ischaemia may 
develop in some 650 of all hospitalized stroke patients treated with 
hypotensive drugs. 
After stroke, the blood pressure is usually increased. It is still 
being debated whether post-stroke hypertension has to be treated. 
There are reports showing that lowering of post-stroke hypertension 
may be dangerous and can aggrevate cerebral ischaemia. We studied the 
spontaneous course of blood pressure in patients admitted for cere-
bral infarction and TIA. This study is presented in Chanter 7. In 42 
of the 63 patients studied blood pressure was increased on the day of 
admission. During the study period antihypertensive or diuretic medi-
cation was not started or changed. Blood pressure fell in the next 
days, mainly on the second day after admission, to a plateau level 
reached on the fifth day. The pattern of the blood pressure course 
was comparable for patients with cerebral infarction and TIA; the 
level of blood pressure of the TIA patients however, was lower on all 
days after the event than that of the patients with cerebral infarc-
tion. Only 3 patients remained (slightly) hypertensive until dis-
charge from the hospital. In 48 patients blood pressure values were 
available as measured two to six months after discharge, without 
having a change in antihypertensive or diuretic medication; in 14 of 
these patients hypertensive blood pressure figures were measured at 
that time. The conclusion of this study is that, after an early in-
crease in blood pressure, on the first day after cerebral infarction 
or TIA, there is a spontaneous fall in the next days to normotensive 
levels in most patients. Treatment of hypertension in the acute phase 
of cerebral infarction or TIA is therefore in most cases not necessa-
ry and may even be dangerous. After discharge, blood pressure may 
increase again; it is therefore advisable to monitor the blood 
pressure a few months after the event. 
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The cause of post-stroke hypertension is not clear. The stress of the 
event and neuronal (dys)régulâti on of blood pressure as a result of 
the brain damage have been suggested as possible explanations. In 
Chapter 8 a preliminary study on the course of both venous and 
urinary catecholamines and plasma renin activity (PRA) in relation to 
blood pressure measured the first 3 days after cerebral infarction is 
presented. The study comprises 10 patients. As expected, blood 
pressure fell on the second and the third day after the event. There 
was a significant fall in plasma epinephrine concentration on the 
third day. The plasma norepinephrine values remained constant on all 
three days. There was a marked and significant increase in PRA on the 
third day; the value was doubled as compared with the first day. No 
significant correlation was found between course of blood pressure 
and plasma catecholamines or PRA. When blood pressure was correlated 
with urinary catecholamines, however, a significant correlation was 
found for epinephrine and dopamine, but not for norepinephrine. It 
was concluded that the changes in blood pressure after cerebral 
infarction are mediated at least in part by changes in catecholamine 
production. 
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SAMENVATTING EN CONCLUSIES 
SAMENVATTING EN CONCLUSIES 
In dit proefschrift beschrijven wij allereerst ons onderzoek met be-
trekking tot herseninfarcering als mogelijke bijwerking van medica-
menteuze behandeling van hoge bloeddruk bij oudere patiënten. 
De laatste jaren zijn er in de literatuur steeds meer publicaties, 
die erop wijzen dat adequate behandeling van hoge bloeddruk ook bij 
oudere patiënten het ontstaan van hart- en vaatziekten, en ook het 
herseninfarct kan voorkómen. Mede door de vergrijzing van de bevol-
king, is het derhalve te verwachten dat steeds meer ouderen met anti-
hypertensieve geneesmiddelen zullen worden behandeld. 
Bij oudere patiënten bestaan vaak een aantal ziekten naast elkaar, 
waardoor het noodzakelijk is dat zij met verschillende medicamenten 
behandeld worden. Juist door het gelijktijdig gebruik van geneesmid-
delen, die eikaars werking kunnen beïnvloeden, en ook tengevolge van 
de veranderde verwerking van het medicament in het lichaam (zoals 
veranderde uitscheiding) en de vaak veranderde reactie op een genees-
middel (zoals grotere of kleinere gevoeligheid), komen bij oudere pa-
tiënten tweemaal zoveel bijwerkingen voor als bij jongere. Daarom is 
kennis van de mogelijke interacties van geneesmiddelen en van de wij-
ziging van de werking van geneesmiddelen met het stijgen van de leef-
tijd, van groot belang om ongewenste werkingen van medicijnen te 
voorkomen. 
Elk geneesmiddel veroorzaakt bijwerkingen. Herkenning van een ziekte-
verschijnsel als bijwerking is soms gemakkelijk, maar meestal is het 
moeilijk om een aandoening als ongewenste werking van een medicament 
te onderkennen. Nog moeilijker wordt het, als een geneesmiddel, dat 
voorgeschreven is om een bepaalde ziekte te voorkomen, juist deze 
ziekte als bijwerking heeft. Meestal zal in een dergelijk geval de 
ziekte niet als bijwerking van het preventief gegeven medicament wor-
den aangemerkt, maar eerder als een falen van de preventie. Wij be-
studeerden de mogelijkheid van een herseninfarct als bijwerking van 
geneesmiddelen voorgeschreven voor hypertensie. De reden om deze 
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mogelijke bijwerking te gaan bestuderen, wordt in Hoofdstuk 1 
beschreven. Het doel van de studie was, de vraag te beantwoorden of 
genoemde bijwerking voorkomt, en zo ja, of deze vooral door bepaalde 
geneesmiddelen optreedt, in hoeverre de ouderen een risicogroep 
vormen de bijwerking te krijgen en in welke frequentie de bijwerking 
optreedt. 
Wanneer men van een ziekteverschijnsel vermoedt, dat het door een 
medicament veroorzaakt wordt, dan dient het ziekteverschijnsel op 
zijn oorzakelijk verband met het geven van het geneesmiddel, de toe-
schrijfbaarheid, beoordeeld te worden, om het te kunnen classificeren 
als "onwaarschijnlijk, mogelijk, waarschijnlijk of zeker". Er zijn 
verscheidene methoden gepubliceerd om deze oorzakelijkheid te 
bepalen. Wanneer deze methoden echter op hetzelfde geval worden toe-
gepast, dan wordt de relatie tussen geneesmiddel en vermoede bijwer-
king vaak verschillend beoordeeld. Ook wanneer één methode op een be-
paald geval werd toegepast door verschillende onderzoekers werden 
verschillende uitkomsten verkregen. Het vaststellen van een ziekte-
verschijnsel als qeneesmiddelenbijwerking is derhalve niet eenvoudig. 
In Hoofdstuk 2 worden twee belangrijke methoden ter beoordeling van 
bijwerkingen beproefd bij pogingen vast te stellen in hoeverre het 
herseninfarct kan optreden als bijwerking van het diureticum furose-
mide, qegeven ter behandeling van hoge bloeddruk, bij de door ons 
opgespoorde en verdachte gevallen. Enkel omdat er sprake was van een 
aanvaardbare tijdsrelatie tussen het geven van de furosemide en het 
optreden van het herseninfarct, werd de vermoede bijwerking als 
"mogelijk" beoordeeld. Belangrijke onderdelen van de beoordelingsme-
thoden, zoals verdwijnen van de ziekteverschijnselen na staken van 
het medicament, en hernieuwd optreden van de ziekteverschijnselen, 
nadat het medicament opnieuw gegeven werd, konden echter niet benut 
worden, aangezien het herseninfarct vaak blijvende ziekteverschijnse-
len teweegbrengt. Omdat hypertensie juist de belangrijkste risicofac-
tor vormt voor het krijgen van een herseninfarct, werd dit als goede 
alternatieve verklaring aangemerkt. De patiënten, van wie wij ver-
moedden dat zij een herseninfarct als gevolg van hun antihypertensie-
ve therapie gekregen hadden, hadden allen evenwel een opmerkelijke en 
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niet verwachte daling van de bloeddruk, gemeten kort na het infarct 
en zij vertoonden allen een verhoogde hematocriet. Deze ons inziens 
belangrijke factoren, konden niet in de methoden verwerkt worden. 
Derhalve werd geconcludeerd dat de meest gebruikte methoden, ter be-
oordeling van een geneesmiddelenbijwerking, niet geschikt zijn om te 
bepalen of en in hoeverre het herseninfarct kan optreden als bijwer-
king van (onjuiste) hypertensiebehandeling. 
In Hoofdstuk 3 wordt een overzicht gegeven van de in de literatuur 
beschreven gevallen van hersenischemie ontstaan door geneesmiddelen. 
Wij verzamelden 44 van dergelijke gevallen. De hersenischemie werd 
veroorzaakt door allerhande bloeddrukverlagende middelen zoals dia-
zoxide, nitroprusside, lisdiuretica, methyldopa, vaatverwijders, 
betablokkers en angiotensine-converting-enzym remmers. Wanneer de 
daling van de gemiddelde arteriële bloeddruk (MAP), welke door de me-
dicamenten teweeg was gebracht, gerelateerd werd aan de leeftijd van 
de patiënten, werd geconstateerd dat bij jongere patiënten steeds een 
aanzienlijke daling van de MAP was opgetreden, terwijl bij de oudere 
een veel geringere daling van de MAP tot hersenischemie aanleiding 
had gegeven. Geconcludeerd werd dat speciaal oudere patiënten risico 
lopen hersenischemie als bijwerking van hypertensiebehandeling te 
krijgen. Ter verklaring is te denken aan een verminderde gevoeligheid 
van de baroreceptorreflex op oudere leeftijd, een mogelijk falen van 
de autoregulatie van de hersenen, waardoor de hersendoorbloeding 
direct afhankelijk is van de bloeddruk, en een daling van de hersen-
doorbloeding met het stijgen van de leeftijd. 
Hoofdstuk 4 beschrijft het vóórkomen van genoemde bijwerking onder 
verpleeghuispatiënten. Daartoe werd een vragenlijst verstuurd naar 
de medisch directeuren van de 322 Nederlandse verpleeghuizen, omdat 
verondersteld werd dat patiënten met een herseninfarct, ontstaan ten-
gevolge van hypertensiebehandeling, aldaar gevonden zouden kunnen 
worden. De respons op de enquête bedroeg 55%. Er werden 30 gevallen 
gemeld door 25 verpleeghuisartsen. Allerlei bloeddrukverlagende 
middelen werden gerapporteerd, maar vooral furosemide en methyldopa. 
Van de 30 gevallen waren er 9 goed gedocumenteerd met volledige 
opgaaf van bloeddrukken, zoals gemeten voor instelling van de 
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behandeling en direct na het ontstaan van de verschijnselen van 
hersenischemie. Bij alle negen (oudere) patiënten was er sprake van 
een aanzienlijke bloeddrukdaling. Uit deze studie werd geconcludeerd 
dat behandeling van hypertensie bij oudere patiënten voorzichtig en 
met de juiste middelen dient te geschieden, waarbij een geleidelijke 
daling van de bloeddruk moet worden nagestreefd, ten pinde hersen-
letsel te voorkomen. 
In Hoofdstuk 5 wordt een studie beschreven, verricht onder 178 pa-
tiënten, die in een algemeen ziekenhuis werden opgenomen wegens een 
herseninfarct of een zogenaamde transient ischaemic attack (TIA). Bij 
100 van deze patiënten waren bloeddrukqegevens beschikbaar, verkregen 
via de huisarts en gemeten enkele dagen tot maximaal 1 jaar voor het 
ontstaan van de hersenischemie. Alleen deze 100 patiënten werden in 
de studie betrokken. Bij zeven van hen was in de 3 weken voorafgaande 
aan de hersenschade, antihypertensieve dan wel diuretische medicatie 
gestart of de dosis ervan verhoogd. Zij werden alle zeven getroffen 
door een herseninfarct. Bij drie van hen was furosemide gestart 
wegens hypertensie, bij twee wegens decompensatie van het hart. Bij 
één patiënt was de furosemidedosis verhoogd wegens oedeem van de 
enkel en bij één was de dosis van het combinatiepreparaat Adelphan-
EsidrexR verhoogd wegens persisteren van de hoge bloeddruk. De 
bloeddruk van de 100 patiënten, zoals gemeten kort na opname, werd 
vergeleken met de waarde oogegeven door de huisarts. Rij 71 patiënten 
werd een stijging van de bloeddruk geconstateerd en bij 29 een daling 
na het hersenletsel. De 3 patiënten, aan wie furosemide gegeven was 
wegens hypertensie, vertoonden de grootste daling van de bloeddruk 
van alle patiënten (een daling van de MAP van respectievelijk 18, 19 
en 22%). De patiënt bij wie de dosis van Aldephan-Esidrex^ was 
verhoogd, had een daling van de MAP van 12%. Bij deze vier patiënten 
waren er ook tekenen van bloedindikking (hoge hematocrietwaarde). 
Naar onze mening heeft bij deze 4 oudere patiënten de start (of 
verandering) van de medicatie een belangrijke bijdrage geleverd in 
het ontstaan van het herseninfarct. Bij de andere 3 patiënten was er 
een geringere daling (10%) of zelfs een toename (5 en 15%) van de 
MAP, en er waren geen tekenen van bloedindikking. Omdat bij hen ook 
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andere risicofactoren voor het ontstaan van een herseninfarct aanwe-
zig waren (boezemfibrilieren met een snelle kamerfrequentie en staken 
van acenocoumarol 1 week voor het ontstaan van het infarct) werd de 
relatie met de medicatiewijziging als minder waarschijnlijk beoor-
deeld. Uit deze studie werd geconcludeerd dat vooral de sterk werken-
de lisdiuretica, zoals furosemide, een zodanige bloeddrukdaling 
teweeg kunnen brengen, dat er daardoor hersenischemie kan ontstaan. 
Omdat er vele betere en veiligere antihypertensieve middelen bestaan, 
dienen de lisdiuretica dan ook niet ter behandeling van hoge bloed-
druk te worden voorgeschreven. 
Hoofdstuk 6 is de Engelse vertaling van het Nederlandse artikel, aan-
geboden aan het Nederlands Tijdschrift voor Geneeskunde. Het doel van 
dit te publiceren artikel is, om genoemde bijwerking onder de aan-
dacht van alle Nederlandse artsen te brengen. Er werd een selectie 
gemaakt uit de 100 patiënten, zoals beschreven in Hoofdstuk 5, waar-
bij alleen de 54 patiënten met een herseninfarct, die antihyperten-
sieve dan wel diuretische medicatie gebruikten, werden bestudeerd. In 
deze studie worden de ziektegeschiedenissen van de 3 patiënten, die 
met furosemide waren gestart wegens hypertensie, gepresenteerd. Uit 
deze studie kan worden opgemaakt, dat bij circa 6% van de patiënten 
die met een herseninfarct in een ziekenhuis werden opgenomen, en 
antihypertensieve medicatie gebruikten, deze medicatie heeft bijge-
dragen tot het ontstaan van de hersenischemie. 
Het is bekend dat na een herseninfarct de bloeddruk meestal is ver-
hoogd. Of deze "post-stroke" hypertensie behandeld moet worden, staat 
nog steeds ter discussie. Er zijn meldingen in de literatuur, dat het 
verlagen van de bloeddruk na een herseninfarct gevaarlijk kan zijn, 
in de zin dat daardoor de hersenischemie toeneemt en het qe'infarceer-
de gebied vergroot wordt. Wij bestudeerden het spontane bloeddrukbe-
loop bij patiënten, die opgenomen waren wegens een herseninfarct of 
TIA. Deze studie is beschreven in Hoofdstuk 7. Tijdens de studieperi-
ode werd antihypertensieve of diuretische medicatie niet gestart of 
gewijzigd. Er werden 63 patiënten bestudeerd. Bij 42 patiënten {67%) 
werd een verhoogde bloeddruk gevonden op de eerste dag van ooname. In 
de volgende dagen trad er een daling van de bloeddruk op, welke op de 
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2e dag na opname het grootst was. Het bloeddrukniveau stabiliseerde 
zich op de 5e dag. Het patroon van het bloeddrukbeloop van patiënten 
met een herseninfarct en TIA was identiek, waarbij het bloeddrukni-
veau bij de patiënten met een TIA op alle 5 dagen na opname lager lag 
dan dat van de patiënten met een herseninfarct. Vlak voor ontslag uit 
het ziekenhuis werd bij nog slechts 3 patiënten (5%) een (licht) ver-
hoogde bloeddruk gemeten. Van 48 patiënten waren bloeddrukgegevens 
beschikbaar, gemeten twee tot zes maanden na ontslag uit het zieken-
huis. Nu werd bij 14 patiënten (29%) een hypertensie vastgesteld. Uit 
deze studie wordt geconcludeerd, dat na een aanvankelijke bloeddruk-
stijging op de eerste dag na ontstaan van hersenletsel, de bloeddruk 
in de volgende dagen, en met name op de 2e dag na opname, soontaan 
daalt tot normale waarden bij de meeste patiënten. Behandeling van 
hoge bloeddruk in de acute fase van een herseninfarct of TIA is der-
halve in de meeste gevallen onnodig en kan zelfs gevaarlijk zijn. Na 
ontslag uit het ziekenhuis blijft controle van de bloeddruk noodzake-
lijk, daar deze bij een aantal patiënten weer stijgt. 
De oorzaak van "post-stroke" hypertensie is niet duidelijk. Een moge-
lijke verklaring wordt gevonden in de stress, die het gebeuren met 
zich meebrengt, maar ook ontregeling van de bloeddruk te wijten aan 
de hersenschade of juist een regeling van de bloeddruk door de 
hersenen, als reactie op de hersenschade, is gesuggereerd. 
In Hoofdstuk 8 wordt het beloop van de catecholamineconcentraties in 
bloed en urine en van plasma-renine-activiteit (PRA) in relatie tot 
de bloeddruk beschreven en wel in de eerste 3 dagen na een hersenin-
farct. Er konden 10 patiënten worden bestudeerd. Zoals verwacht, 
daalde de bloeddruk op de 2e en 3e dag ten opzichte van de Ie dag na 
opname. Er was een statistisch significante daling van de plasma 
adrenaline concentratie op de 3e dag. De plasma noradrenaline concen-
traties bleven gedurende de 3 dagen op een constant niveau. Er was 
een aanzienlijke en significante stijging van de PRA op de 3e dag; de 
concentratie verdubbelde ten opzichte van die van de Ie dag. Er werd 
geen significante correlatie gevonden tussen het bloeddrukbeloop en 
de plasma catecholamine concentraties of PRA. Wel bestond er een sig-
nificante correlatie tussen de catecholamine concentraties van adre-
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nal ine en dopamine in de urine, maar niet van noradrenaline. De con-
clusie is, dat de bloeddrukverandering na een herseninfarct minstens 
ten dele wordt bewerkstelligd door of via verandering in catecholami-
neproduktie. 
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Allen die aan de totstandkoming van dit proefschrift hebben bijgedra-
gen, wil ik danken. Allereerst de patiënten voor hun onmisbare mede-
werking aan het onderzoek. De vele huisartsen en verpleeghuisartsen 
wil ik danken voor hun bereidwilligheid mij de nodige informatie te 
verschaffen. 
R. Meyboom, hoofd van het Bureau Bijwerkingen Geneesmiddelen 
(Rijswijk) dank ik voor zijn enthousiaste medewerking. 
E. Poels, neuroloog in het Canisius-Wilhelmina Ziekenhuis, werkte, 
zeer bereidwillig, aan een groot deel van het onderzoek mee, en ik 
dank hem voor zijn steun, adviezen en de gastvrijheid zijn afdeling 
voor het onderzoek open te stellen, dit met instemming van zijn 
collega's Dr. С Frenken en Dr. M. Prick. Voorts kan ik terugzien op 
een zeer prettige samenwerking met en enorme hulp van de veroleging 
van afdeling 19 (hoofd Mw. W. van Sambeek) van het Canisius-Wilhel­
mina Ziekenhuis. 
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laboratorium (hoofd destijds J. Kok). Ook ben ik dank verschuldigd 
aan K. Lamers, klinisch chemicus, voor zijn medewerking. 
De tekeningen werden vervaardigd door J. Konings en C. Nicolasen van 
de afdeling Medische Illustratie, en vervolgens werden fotografische 
afdrukken gemaakt OD de afdeling Medische Fotografie. 
Het verzamelen van literatuur was mogelijk door medewerking van het 
personeel van de Medische Bibliotheek (hoofd Mw. S. Bakker) en van 
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De correctie van de engelse taal werd, immer vlot, verricht door de 
heer Th. van Winsen. 
Gemma Wessel-Hooqstraaten ben ik veel dank verschuldigd voor de 
enorme inzet en zorgvuldigheid, waarmee zij de manuscripten op de 
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tekstverwerker heeft gezet en met veel geduld steeds heeft bijge-
werkt. Anky Verweyen en Ans Ruesen-Maandag waren bereid in te 
springen wanneer het nodig was. 
Tot slot wil ik Marjan bedanken voor haar secretariële werk in de 
weekeinden en haar onmisbare steun. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 23 maart 1953 geboren te 
Haarlem. In 1972 behaalde hij aan het Canisius College te Nijmegen 
het einddiploma Gymnasium β. 
Na het eerste jaar uitgeloot te zijn, studeerde hij vanaf 1973 
Geneeskunde aan de Katholieke Universiteit te Nijmegen. 
In 1978 behaalde hij het doctoraalexamen en in 1980 het artsexamen. 
In oktober 1980 begon hij zijn opleiding tot internist in de 
universiteitskliniek voor Inwendige Geneeskunde te Nijmegen (hoofd 
Prof.Dr. A. van 't Laar). 
Van mei 1983 tot december 1985 was hij gedeeltelijk werkzaam binnen 
de werkgroep Klinische Farmacologie en Farmacokinetiek (leider 
Prof.Dr. F.W.J. Gribnau) van het laboratorium Farmacologie (hoofd 
Prof.Dr. C.A.M, van Ginneken) in welke periode het onderzoek verricht 
werd, waarvan dit proefschrift een verslag is. 
Op 1 oktober 1985 voltooide hij zijn opleiding tot internist; vanaf 
1 januari 1986 volgt hij de opleiding tot klinisch geriater in het 
Christelijk Psychiatrisch Centrum Bloemendaal te 's Gravenhage 
(opleider J. van Nieuwkerk). 
Hij is getrouwd met Marjan Wessels. 
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STELLINGEN 
I 
Wegens zijn krachtige diuretische werking, met kans op ontstaan van 
hypovolemie en hersenischemie is furosemide, in "gewone" doseervnrm 
van snel geresorbeerd tablet, niet geschikt als anti-hypertensief 
middel. 
(dit proefschrift) 
II 
Bij' bej'aarde patiënten kan reeds door een relatief geringe bloeddruk-
verlaging hersenischemie ontstaan. 
(dit proefschrift) 
III 
Tenzij' er tekenen zijn van hypertensieve encephalopathie dient 
"post-stroke" hypertensie niet met antihypertensieve middelen 
behandeld te worden. 
(dit proefschrift) 
IV 
Bij nagenoeg alle patiënten met een herseninfarct daalt de gestegen 
bloeddruk soontaan binnen vijf dagen na het accident tot normale 
waarden. 
(dit proefschrift) 
V 
De bloeddrukveranderingen, die kort na een herseninfarct optreden, 
zijn, minstens ten dele, toe te schrijven aan verhoogde produktie van 
catecholaminen. 
(dit proefschrift) 
VI 
De huidige methoden ter bepaling van de toeschrijfhaarheid van bij-
werkingen van qeneesmiddelen zijn onvoldoende bruikbaar, aangezien 
zij niet toegespitst zijn op één bepaald orgaan. 
VII 
In geval van een qeneesmiddelexantheem tijdens therapie voor exacer-
batie van CARA, waarbij vaak zowel antibiotica als aminophylline 
worden gegeven, dient als de veroorzaker van de allergie naast aan 
het antibioticum, aan ethyleendiamine gedacht te worden. 
(Berg v.d. W en Ketel v.d. W, lied Τ Geneesk 1983; 127: 1801-2) 
(eigen waarneming) 
VIII 
Digitalisatie volgens de vuistregel van Birkenhäger, thans niet meer 
door hemzelf, maar wel door anderen gehanteerd, zal bij de meeste 
patiënten ouder dan 70 jaar tot onderdosering leiden. 
(Birkenhäger W, Ned Τ Geneesk 1982; 126_: 394-5) 
IX 
Bij de behandeling van decompensatio cordis is digoxine niet het 
geneesmiddel van de eerste keuze, wanneer er een sinusritme bestaat. 
(Lipkin en Poole-Wilson P, Br Med J 1985; 291_: 993-6) 
X 
Aangezien de farmacokinetiek van geneesmiddelen bij beiaarden gewii-
ziad kan zijn ten opzichte van die van jongeren, dient onderzoek van 
elk geneesmiddel naar dit aspect te geschieden. 
XI 
De gewijzigde kinetiek van naproxen op oudere leeftijd is voorname-
lijk toe te schrijven aan veranderde binding van dit geneesmiddel aan 
serumeiwitten. 
(Upton FA e.a., Br J Clin Pharmacol 1984; 18: 207-14) 
XII 
Het bestaansrecht van het specialisme klinische geriatrie wordt in 
hoge mate geschraagd door de constatering dat hoogbejaarde patiënten 
veelal niet adequaat medisch behandeld worden. 
XIII 
Het medisch adaqium "qui bene purgat, bene curat" i s i n fe hooqste 
mate geldig in de geriatrische praktijk. 
XIV 
Mits met de juiste kennis en toewijding verzorgd, is de roodwang-
moerasschildoad in gevangenschap een lanq leven beschoren. 
P.A.F. Jansen 
Nii'meqen, 2Я november 1986 



